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Abstract
EFSA requested the Scientiﬁc Committee to develop a guidance document on the use of the weight of
evidence approach in scientiﬁc assessments for use in all areas under EFSA’s remit. The guidance
document addresses the use of weight of evidence approaches in scientiﬁc assessments using both
qualitative and quantitative approaches. Several case studies covering the various areas under EFSA’s
remit are annexed to the guidance document to illustrate the applicability of the proposed approach.
Weight of evidence assessment is deﬁned in this guidance as a process in which evidence is integrated to
determine the relative support for possible answers to a question. This document considers the weight of
evidence assessment as comprising three basic steps: (1) assembling the evidence into lines of evidence
of similar type, (2) weighing the evidence, (3) integrating the evidence. The present document identiﬁes
reliability, relevance and consistency as three basic considerations for weighing evidence.
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Summary
The European Safety Authority (EFSA) requested the Scientiﬁc Committee (SC) to develop a
guidance document on the use of the weight of evidence approach in scientiﬁc assessments for use in
all areas under EFSA’s remit.
The guidance document addresses the use of weight of evidence approaches in scientiﬁc
assessments using both qualitative and quantitative approaches. Several case studies covering the
various areas under EFSA’s remit are annexed to the guidance document to illustrate the applicability
of the proposed approach.
In developing the guidance, the Working Group (WG) of the SC took into account other EFSA
activities and related European and international activities to ensure consistency and harmonisation of
methodologies in order to provide an international dimension to the guidance and avoid duplication of
the work.
This guidance document is intended to guide EFSA Panels and staff on the use of the weight of
evidence approach in scientiﬁc assessments. It provides a ﬂexible framework that is applicable to all
areas within EFSA’s remit, within which assessors can apply those methods which most appropriately
ﬁt the purpose of their individual assessment.
Weight of evidence assessment is deﬁned in this guidance as a process in which evidence is
integrated to determine the relative support for possible answers to a question. This document
considers the weight of evidence assessment as comprising three basic steps: (1) assembling the
evidence into lines of evidence of similar type, (2) weighing the evidence, (3) integrating the evidence.
The present document identiﬁes reliability, relevance and consistency as three basic considerations
for weighing evidence. They are deﬁned in terms of their contributions to the weight of evidence
assessment: Reliability is the extent to which the information comprising a piece or line of evidence is
correct. Relevance is the contribution a piece or line of evidence would make to answer a speciﬁed
question, if the information comprising the line of evidence was fully reliable. Consistency is the extent
to which the contributions of different pieces or lines of evidence to answering the speciﬁed question
are compatible.
While no speciﬁc methods are prescribed, a list of criteria for comparing weight of evidence
methods is provided to assist in evaluating the relative strengths and weaknesses of the different
methods. The criteria do not necessarily have equal importance: their relative importance may be
considered on a case-by-case basis when planning each weight of evidence assessment.
All EFSA scientiﬁc assessments must include consideration of uncertainties, reporting clearly and
unambiguously what sources of uncertainty have been identiﬁed and what their impact on the
assessment outcome is.
Reporting should be consistent with EFSA’s general principles regarding transparency and reporting.
In a weight of evidence assessment, this should include justifying the choice of methods used,
documenting all steps of the procedure in sufﬁcient detail for them to be repeated, and making clear
where and how expert judgement has been used. Reporting should also include referencing and, if
appropriate, listing or summarising all evidence considered, identifying any evidence that was
excluded; detailed reporting of the conclusions; and sufﬁcient information on intermediate results for
readers to understand how the conclusions were reached.
EFSA Panels and Units are encouraged to review their existing approaches to weight of evidence
assessment in the light of the guidance document, and to consider in particular:
• Whether all pertinent aspects of reliability, relevance and consistency are addressed,
• How to ensure the transparency of weight of evidence assessments,
• Carry out some case studies to assess whether additional methods described in the guidance
would add value to their scientiﬁc assessments.
Guidance on the weight of evidence
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1. Introduction
1.1. Background and Terms of Reference as provided by EFSA
EFSA’s Science Strategy 2012–2016 has identiﬁed four strategic objectives: (1) further develop
excellence of EFSA’s scientiﬁc advice, (2) optimise the use of risk assessment capacity in the European
Union (EU), (3) develop and harmonise methodologies and approaches to assess risks associated with
the food chain, (4) strengthen the scientiﬁc evidence for risk assessment and risk monitoring. In this
context, the harmonisation and development of new methodologies for risk assessment and scientiﬁc
assessments is of critical importance to deliver EFSA’s science strategy. For this purpose, a number of
projects have recently started at the European Food Safety Authority (EFSA) to address individual and
cross-cutting methodological issues within the whole scientiﬁc assessment landscape. The Assessment
Methodological unit (AMU) of EFSA has started a project (PROMETHEUS) with the objective of
supporting the coordination and consistency of all EFSA projects that aim at developing or reﬁning
methodological approaches. Such an umbrella project will provide a deﬁnition of the guiding principles
for evidence-based assessments and a collection of available approaches and will identify areas where
methods or tools are needed to fulﬁl such guiding principles.1
In July 2013, the Scientiﬁc Committee (SC) of EFSA published an opinion on ‘priority topics for the
development of risk assessment guidance by EFSA’s SC’ which used a number of criteria to make
recommendations for the preparation of new or the revision of existing guidance documents as
follows:
• Across Panel relevance
• Critical importance including urgency of topic to be addressed for several Panels
• Topic not being addressed by an individual Panel
• Sufﬁcient information available to develop meaningful guidance
• International dimension.
From this prioritisation exercise, the SC opinion identiﬁed three priority topics for 2014: uncertainty
analysis, biological relevance, and the use of the weight of evidence (weight of evidence) in scientiﬁc
assessments (EFSA Scientiﬁc Committee, 2013).
The latter is the subject of this project. The weight of evidence has been deﬁned by the WHO as ‘a
process in which all of the evidence considered relevant for a risk assessment is evaluated and
weighted’ (WHO, 2009). The SC of EFSA used the WHO deﬁnition and pointed out that evidence can
be derived from several sources such as white literature (peer reviewed scientiﬁc publications), grey
literature (reports on websites of governmental, nongovernmental, intragovernmental agencies, etc.)
and black literature (conﬁdential reports). In order to increase transparency in the risk and other
scientiﬁc assessment processes, it is important to provide a methodology to select, weigh and
integrate the evidence in a systematic, consistent and transparent way to reach the ﬁnal conclusions
and to identify related uncertainties (SCENIHR, 2012; EFSA Scientiﬁc Committee, 2013). In addition,
the SC of EFSA noted that part of the overall weighing of the evidence deals with the evaluation of
equivalent or similar questions performed by other international bodies and the adequacy of such
evaluations should be judged by EFSA before taking them into account. This is particularly helpful in
cases for which the information available is so extensive that it is beyond the capability of a single
evaluation to judge each individual study, report, publication by itself. In addition, systematic reviews
(SRs) may be very useful. However, the adequacy of the process, the pertinence to the risk
assessment, the nature of the question and the inclusion and exclusion criteria should be transparently
evaluated by EFSA before taking SRs into account (EFSA Scientiﬁc Committee, 2013). Considering the
example of chemical risk assessment, the weight of evidence approach requires expert judgement of
distinct lines of evidence (in vivo, in vitro, in silico, population studies, modelled and measured
exposure data, etc.), which may come from studies conducted according to ofﬁcial guidelines (e.g.
OECD) or from non-standardised methodologies. In this context, data from all sources and categories
of literature should be considered for the risk assessment processes, as appropriate to determine their
quality and relevance. These considerations should then be reﬂected in the relative weight given to the
evidence in the scientiﬁc assessment and transparently taken into account in the overall evaluation of
uncertainty (EFSA Scientiﬁc Committee, 2013). It is therefore proposed that the SC of EFSA develop
guidance on the use of the weight of evidence approach in scientiﬁc assessments.
1 For current information on PROMETHEUS see: https://www.efsa.europa.eu/en/methodology/evidence
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Terms of Reference
EFSA requests the SC to develop a guidance document on the use of the weight of evidence
approach in scientiﬁc assessments for use in all areas under EFSA’s remit.
The guidance document should address the use of the weight of evidence in scientiﬁc assessments
using both qualitative and quantitative approaches. Several case studies covering the various areas
under EFSA’s remit should be annexed in the guidance document to illustrate the proposed approaches.
In developing the guidance, the Working Group (WG) of the SC should take into account other
EFSA activities and related European and international activities to ensure consistency and
harmonisation of methodologies, to provide an international dimension to the guidance and avoid
duplication of the work.
In line with EFSA’s policy on openness and transparency, EFSA will publish a draft version of the
guidance document for public consultation to invite comments from the scientiﬁc community and
stakeholders. Subsequently, the guidance document and the results of the public consultation should
be presented at an international event after publication.
1.2. Interpretation of the Terms of Reference
In the context of risk assessment, various formal deﬁnitions and synonyms have been offered by
IPCS (2004), US EPA (2000), WHO FAO, US National Research Council’s Committee, SCHER, SCENIHR,
SCCS (2013) on Improving Risk Analysis Approaches for the phrase ‘weight of evidence’ or ‘evidence
synthesis’.
When addressing the mandate, the SC acknowledged that the issue of weight of evidence
approaches in risk assessment encompasses aspects related to the reliability of the various pieces of
evidence used in the assessment.
In order for the guidance document to address the use of the weight of evidence approaches in
scientiﬁc assessments using both qualitative and quantitative approaches, a list of the available
approaches used globally has been provided together with several case studies from various areas
under EFSA’s remit to illustrate the proposed approaches.
In developing the guidance, the WG of the SC has taken into account other EFSA activities and related
European and international activities to ensure consistency and harmonisation of methodologies, to
provide an international dimension to the guidance and avoid duplication of the work.
In particular:
• relevant guidance published by the SC on related subjects (transparency in risk assessment,
uncertainty in exposure assessment, statistical signiﬁcance and biological relevance (EFSA,
2006, 2009, 2011) and the latest draft guidance documents on uncertainty and biological
relevance that are being developed concomitantly.
• the guidance on uncertainty analysis in risk assessment. It deals speciﬁcally with reporting and
analysing uncertainties using qualitative and quantitative methods for all work within EFSA‘s
remit. The overlaps with the weight of evidence approach should be carefully taken into
account by both WGs to ensure that the weight of evidence and uncertainty guidance
documents are consistent, use harmonised methodologies, and do not duplicate the work.
• the guidance on biological relevance for all areas of work within EFSA’s remit. It deals
speciﬁcally with criteria to evaluate biological relevance in scientiﬁc assessments and the
overlaps with the weight of evidence approach should be carefully taken into account by both
WGs to ensure consistency, the use of harmonised methodologies, and to avoid duplication.
• the current work within EFSA on the approach to evidence-based risk assessment to ensure
consistency, the use of harmonised methodologies, and to avoid duplication of the work.
The guidance was also expected to take into account other European and international activities:
• The work of the European Commission’s non-food scientiﬁc committees and other agencies on
weight of evidence approach, and where appropriate, seek their participation for the
development of a harmonised guidance.
Examples include best practices in weight of evidence methodologies, the use of SR in risk
assessment, the WHO application of the weight of evidence approach in relation to the mode of action
framework and other related international developments (EFSA, 2010a; Meek et al., 2014; Perkins
et al., 2015; OECD, 2016; Wittwehr et al., 2016).
Guidance on the weight of evidence
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1.3. Aim and scope of the document
Weighing the evidence is an inherent part of every scientiﬁc assessment performed by EFSA.
Experts review all available data, and come to conclusions based on an assessment of their overall
conﬁdence in the results of all reviewed studies. The approaches and methods used in conducting
such an ‘non-formalised’, inherent weighing of the evidence are mostly not spelled out, however.
The aim of this guidance document is to provide a general framework for considering and
documenting the approaches used to weigh the evidence in answering the main question of each
scientiﬁc assessment or questions that need to be answered in order to provide, in conjunction, an
overall answer. The document further indicates, in general terms, types of qualitative and quantitative
approaches to weigh and integrate evidence, and lists individual methodologies with pointers as to
where details of these can be found. Finally, the document provides suggestions for conducting and
reporting of weight of evidence assessments.
The document does not attempt to prescribe approaches or methods to be used, nor does it
provide a comprehensive description of all methods that can be used.
1.4. Relation to other relevant EFSA guidance documents
The guidance on the use of the weight of evidence approaches builds on the conceptual approach
for scientiﬁc assessments as described in PROMETHEUS (EFSA, 2015b), which describes the overall
process for dealing with data and evidence.
Transparent reporting of all assumptions and methods used, including expert judgement, is
necessary to ensure that the assessment process leading to the conclusions is fully comprehensible.
‘Open EFSA’ aspires both to improve the overall quality of the available information and data used
for its scientiﬁc outputs and to comply with normative and societal expectations of openness and
transparency (EFSA, 2009, 2014a–d). In line with this, EFSA is publishing three separate but closely
related guidance documents to guide its expert Panels for use in their scientiﬁc assessments (EFSA,
2015a–c). These documents address three key elements of the scientiﬁc assessment: the analyses of
Uncertainty, Weight of Evidence assessment and Biological Relevance.
The ﬁrst document provides guidance on how to identify, characterise, document and explain all
types of uncertainty arising within an individual assessment for all areas of EFSA’s remit. The Guidance
does not prescribe which speciﬁc methods should be used from the toolbox but rather provides a
harmonised and ﬂexible framework within which different described qualitative and quantitative
methods may be selected according to the needs of each assessment.
This current document on weight of evidence assessment provides a general framework for
considering and documenting the approach used to evaluate and weigh the assembled evidence when
answering the main question of each scientiﬁc assessment or questions that need to be answered in
order to provide, in conjunction, an overall answer. This includes assessing the relevance, reliability
and consistency of the evidence. The document further indicates the types of qualitative and
quantitative methods that can be used to weigh and integrate evidence and points to where details of
the listed individual methods can be found. The weight of evidence approach carries elements of
uncertainty analysis that part of uncertainty which is addressed by weight of evidence analysis does
not need to be reanalysed in the overall uncertainty analysis, but may be added to.
The third document provides a general framework to addresses the question of biological relevance
at various stages of the assessment: the collection, identiﬁcation and appraisal of relevant data for the
speciﬁc assessment question to be answered. It identiﬁes generic issues related to biological relevance
in the appraisal of pieces of evidence, in particular, and speciﬁc criteria to consider when deciding on
whether or not an observed effect is biologically relevant, i.e. whether it shows an adverse or a
positive health effect. A decision tree is developed to aid the collection, identiﬁcation and appraisal of
relevant data for the speciﬁc assessment question to be answered. The reliability of the various pieces
of evidence used and how they should be integrated with other pieces of evidence is considered by
the weight of evidence guidance document.
EFSA will continue to strengthen links between the three distinct but related topics to ensure the
transparency and consistency of its various scientiﬁc outputs while keeping them ﬁt for purpose.
Guidance on the weight of evidence
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1.5. Audience and degree of obligation
This Guidance is aimed at all those contributing to EFSA assessments and provides a harmonised,
but ﬂexible framework that is applicable to all areas of EFSA’s work and all types of scientiﬁc
assessment, including risk assessment. In line with improving transparency, the SC considers the
application of this guidance to be unconditional for EFSA. Each assessment must clearly and
unambiguously document:
• what evidence was considered and how it was assembled into lines of evidence;
• how the evidence was weighed and integrated including consideration of reliability, relevance
and consistency;
• the conclusion on the weight of evidence question in terms of the range and probability of
possible answers. This can be expressed qualitatively or quantitatively, but should be
quantiﬁed if possible when it directly addresses the Terms of Reference for the assessment.
The document provides guidance on the general principles of the weight of evidence approach but
assessors have the ﬂexibility to choose appropriate methods, and the degree of reﬁnement in applying
them.
2. General framework and principles for weight of evidence
assessment
This section provides a general framework and principles for weight of evidence assessment,
including deﬁnitions of key concepts. Many scientiﬁc assessments involve weighing of evidence,
although this may be implicit rather than explicit and is only sometimes described as ‘weight of
evidence assessment’. The aim of this guidance is to make weight of evidence assessment more
explicit and transparent, and to provide a general framework of principles and approaches which is
applicable to all areas of EFSA’s work. Account is taken of approaches already used by EFSA, by other
EU and international organisations, and in the scientiﬁc literature.
2.1. Weight of evidence assessment and lines of evidence
WHO (2009) has deﬁned weight of evidence assessment as ‘a process in which all of the evidence
considered relevant for a risk assessment is evaluated and weighted’. A recent review by ANSES (2016)
deﬁnes weight of evidence assessment as ‘the structured synthesis of lines of evidence, possibly of
varying quality, to determine the extent of support for hypotheses’. Deﬁnitions and descriptions from a
selection of other relevant publications are presented in Annex B, and reﬂect similar concepts to those
of WHO and ANSES. The core of most deﬁnitions is that weight of evidence assessment is a process
for integrating evidence to arrive at conclusions.
In practice, weighing2 of evidence may occur when estimating quantities, as well as when assessing
hypotheses, and both are relevant to EFSA’s work. Therefore, this document uses a broader deﬁnition,
as follows:
Weight of evidence assessment is a process in which evidence is integrated to determine the
relative support for possible answers to a scientiﬁc question.
The term ‘weight of evidence’ on its own is the extent to which evidence supports possible answers
to a scientiﬁc question. This is what is assessed by weight of evidence assessment, and can be
expressed qualitatively or quantitatively (discussed further in Section 2.3, below).
It is often useful to organise evidence into groups or categories, which are often referred to as lines
of evidence. ANSES (2016) deﬁnes a line of evidence as ‘a set of relevant information of similar type
grouped to assess a hypothesis’. Rooney et al. (2014) use the variant ‘streams of evidence’ which they
describe as referring speciﬁcally to human data, animal data, and ‘other relevant data (including
mechanistic or in vitro studies)’. This document simpliﬁes the ANSES (2016) deﬁnition, replacing
‘relevant information’ with ‘evidence’ and reducing the emphasis on hypotheses, because weight of
evidence assessment may be applied to quantities as well as hypotheses, as mentioned above. This
results in the following general deﬁnition, which is compatible with other uses of the same term in the
literature (see Annex B):
2 The term ‘weighing’ is used in preference to ‘weighting’ in this document, as not all approaches to weighing evidence involve
explicit assignment of ‘weights’.
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A line of evidence is a set of evidence of similar type.
Various terms have been used to refer to distinct elements of information within a line of evidence,
including ‘studies’ and ‘pieces of evidence’. Piece of evidence is a more general term, as it could
refer to a study (or to one of multiple outcomes of a study), or to other types of information including
expert knowledge, experience, a model or even a single observation. In some cases, a line of evidence
may comprise only a single piece of evidence.
Pieces of evidence may show varying degrees of similarity. There is no ﬁxed rule on how much
similarity is required within the same line of evidence. This is for the assessor(s) to decide, and
depends on what they ﬁnd useful for the purpose of the scientiﬁc assessment. For example, in some
assessments, it might be sufﬁcient to treat all human studies as a single line of evidence, whereas in
other assessments it might be helpful to treat different types of human studies as separate lines of
evidence.
The deﬁnition for line of evidence is broadly worded to accommodate different ways in which lines
of evidence may contribute to answering a question. Different lines of evidence for the same question
may be standalone, in the sense that each line of evidence offers an answer to the question without
needing to be combined with other lines of evidence. It is important to distinguish these from
complementary lines of evidence, which can only answer the question when they are combined.
Multiple experiments measuring the same parameter are examples of standalone lines of evidence,
whereas data on hazard and exposure are complementary lines of evidence for risk assessment
because both are necessary and must be combined to assess risk. The distinction between
complementary and standalone lines of evidence is important because it has practical implications in
weight of evidence assessment (see Section 4). Note that a single question may be addressed by a
combination of standalone and complementary lines of evidence.
Assessors often refer to ‘data gaps’, where types or lines of evidence that would have been useful
are lacking. These are easier to detect in regulatory assessments, where lists of required data are
established in legislation or guidance. Although weight of evidence assessment is described in terms of
evaluating available evidence it also takes account of data gaps. This is because, when a particular
type of evidence is absent, the contribution it could have made will also be absent. How much this
affects the assessment will depend on the extent to which the available evidence can answer the
question itself, or substitute for what is missing (e.g. by read-across) (see also Section 4).
2.2. When to use weight of evidence approaches
In general, the purpose of weight of evidence assessment is to answer a scientiﬁc question, as
implied in the preceding section. EFSA assessments address questions posed by their Terms of
Reference. In some cases, a question in the Terms of Reference may be addressed directly, but in
other cases, it is beneﬁcial to divide the primary question into two or more subsidiary questions (EFSA,
2015b).
Weighing of evidence is involved, either explicitly or implicitly, wherever more than one piece of
evidence is used to answer a question. Weight of evidence assessment is not needed for scientiﬁc
questions where no integration of evidence is required.
Thus, a single scientiﬁc assessment may comprise one or many questions and none, some or all of
those questions may require weight of evidence assessment.
Clarifying the questions posed by the Terms of Reference and deciding whether and how to
subdivide them, and whether they require weight of evidence assessment, is part of the ﬁrst stage of
scientiﬁc assessment, often referred to as problem formulation. This may show that the question is
relatively simple and can be addressed directly, by a straightforward assessment. In many
assessments, however, questions may need to be subdivided to yield more directly answerable
questions. In this manner, a hierarchy or tree of questions may be established. Assessment then starts
at the bottom of the hierarchy. The evidence is divided into lines of evidence, as far as is helpful,
assessed, weighed and integrated to answer each question at the bottom of the hierarchy. Integration
continues upwards through the question hierarchy following similar principles, until full integration is
reached to answer the main question deﬁned by the problem formulation.
In some cases, the Terms of Reference for an assessment pose open questions, for example, to
review the state of science on a particular topic. These assessments also require weight of evidence
assessment approaches, because their conclusions generally derive from weighing and integrating
evidence.
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2.3. Weight of evidence conclusions
As implied in the deﬁnition above, the purpose of weighing evidence is to assess the relative
support for possible answers to a scientiﬁc question. In some cases, it may be concluded that the
evidence supports only one answer, with complete certainty. More usually, multiple answers remain
possible, with differing levels of support. In such cases, the conclusion should state the range of
answers that remain possible, and not be reduced to a single answer unless a threshold level of
support for conclusions has been agreed with decision-makers, because this involves risk management
considerations.
When weight of evidence assessment directly addresses the conclusion of a scientiﬁc assessment, its
output will be part of the response to the Terms of Reference for the assessment. In general, decision-
makers need to know the range of possible answers to their questions, and how probable they are,
because this may have important implications for decision-making (EFSA, 2016a–c). Furthermore, it is
important to express this quantitatively when possible, to avoid the ambiguity of qualitative expression
(EFSA, 2012, 2016a–c).
When weight of evidence addresses an intermediate question in a larger assessment, the possible
answers and their relative support needs to be taken into account in subsequent steps of the
assessment. In these cases, relative support may be expressed either qualitatively or quantitatively,
depending on what is convenient for use in the subsequent steps. Qualitative and quantitative
approaches are discussed further in Section 3.
2.4. Steps in weight of evidence assessment
This document considers the weight of evidence assessment as comprising three basic steps:
1) Assembling the evidence,
2) Weighing the evidence,
3) Integrating the evidence.
This corresponds to the three basic steps distinguished by Suter and Cormier (2011, their Figure 3;
see also Suter, 2016). The ﬁrst step involves searching for and selecting evidence that is relevant for
answering the question in hand, and deciding whether and how to group it into lines of evidence. The
second step involves detailed evaluation and weighing of the evidence. In the third step, the evidence
is integrated to arrive at conclusions, which involves weighing the relative support for possible answers
to the question.
Practical guidance for the three basic steps is provided in Section 4. Relevant considerations to be
taken into account in the weighing and integrating steps are discussed in Section 2.5, while qualitative
and quantitative methods for assessing those considerations are discussed in Section 3.
The three steps of weight of evidence assessment, described above, may occur at one or more
points in the course of a scientiﬁc assessment, wherever integration of evidence is required, as
illustrated in Figure 1. The question to be addressed by each weight of evidence assessment is deﬁned
by problem formulation, which is a preceding step in the scientiﬁc assessment as a whole. The output
of weight of evidence assessment feeds either directly or indirectly into the overall conclusion of the
scientiﬁc assessment. Although weight of evidence assessment itself addresses some of the uncertainty
affecting the scientiﬁc assessment (see below), a separate step of uncertainty analysis is still needed
to take account of any other uncertainties affecting the overall assessment. Some assessments will
also include a step of sensitivity analysis or inﬂuence analysis, to identify which evidence and
uncertainties have most inﬂuence on the conclusion.
Any part of the overall assessment may be reﬁned iteratively, when necessary, by returning from
later steps to earlier steps, depending on which steps it is most useful to reﬁne.
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2.5. Key considerations for weighing evidence
Reliability, relevance and consistency are mentioned in many publications on weight of evidence
assessment (see Annex B). These can be seen as three basic considerations in the weight of evidence
assessment: how applicable the evidence is to the question of interest, the quality of the evidence and
how consistent it is with other evidence for the same question. How these three concepts relate to one
another, to the three basic steps of weight of evidence assessment and to the weight of evidence
conclusion are illustrated in Figure 2. Note that relevance and reliability may be considered in both the
ﬁrst and second steps. First, relevance is considered when identifying evidence, and both relevance
and reliability may be considered when selecting which of the identiﬁed evidence to include in the
assessment (sometimes referred to as screening or ﬁltering). However, the selected evidence will vary
in both relevance and reliability and this will be considered in the second step, when weighing the
evidence.
Weight of evidence assessment
1. Assemble the evidence
2. Weigh the evidence
3. Integrate the evidence
Problem formulation
• Define the question(s) for assessment
Uncertainty analysis
• Assess and combine uncertainties from all parts of the overall assessment 
• Identify data gaps
May occur at one or more 
points in the assessment, 
where evidence integration 
is needed
Conclusion of overall assessment
Overall scientific assessment
Figure 1: Diagrammatic illustration of weight of evidence assessment as a 3-step process which may
occur at one or more points in the course of a scientiﬁc assessment
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The present document deﬁnes reliability, relevance and consistency, in terms of their contributions
to the weight of evidence assessment, as illustrated in Figure 2:
Reliability is the extent to which the information comprising a piece or line of evidence is correct,
i.e. how closely it represents the quantity, characteristic or event that it refers to. This includes both
accuracy (degree of systematic error or bias) and precision (degree of random error).
Relevance is the contribution a piece or line of evidence would make to answer a speciﬁed
question, if the information comprising the evidence was fully reliable. In other words, how close is the
quantity, characteristic or event that the evidence represents to the quantity, characteristic or event
that is required in the assessment. This includes biological relevance (EFSA, 2017) as well as relevance
based on other considerations, e.g. temporal, spatial, chemical, etc.
Consistency is the extent to which the contributions of different pieces or lines of evidence to
answering the speciﬁed question are compatible.
These deﬁnitions are compatible with those found in other publications relating to weight of
evidence assessment (e.g. ECHA, 2010; SCENIHR, 2012; Vermeire et al., 2013). Different types of
‘contribution’ are discussed further below.
Other publications mention additional considerations relevant to weight of evidence assessment
including, for example, quality, applicability, coherence, risk of bias, speciﬁcity, biological concordance or
plausibility, biological gradient and many others. Some of these are synonyms for reliability, relevance or
consistency, some refer to combinations of reliability and relevance, and others refer to speciﬁc types of
reliability, relevance or consistency that are important for particular areas of assessment (see Annex B).
For example, in some approaches for assessing reliability, emphasis is placed on particular aspects (e.g.
conformance to GLP) with less consideration of other key aspects of reliability that should also be
assessed, such as bias (Moermond et al., 2017). The reasons for giving particular emphasis to reliability,
relevance and consistency are that they are generic considerations, applicable to every type of
assessment, with deﬁned relationships to the three basic steps of weight of evidence assessment, and a
deﬁned relationship to the weight of evidence conclusion, as illustrated in Figure 2. This makes them
useful to assessors as a conceptual framework for identifying speciﬁc considerations relevant to
particular assessments, and for assessing how they combine to determine the weight of evidence
conclusion. How this can be applied in practice is discussed further in Section 4.
WEIGHT OF EVIDENCE CONCLUSION
LINES OF EVIDENCE
Identify, filter and organise the evidence 
based on consideration of relevance  and reliability
Assemble 
the evidence
Weigh 
the evidence
Integrate 
the evidence
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Assess the relevance  and reliability of the evidence
Assess consistency across the evidence
Includes preliminary consideration of relevance  and reliability
AVAILABLE INFORMATION
Figure 2: Relationship of relevance (including biological relevance), reliability and consistency to the
three basic steps of weight of evidence assessment and to the conclusion for a weight of
evidence question
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2.6. Relation of weight of evidence assessment and uncertainty
Weight of evidence assessment and uncertainty are closely related. For example, SCENIHR (2012)
state that ‘strength of evidence is inversely related to the degree of uncertainty’, while Suter and
Cormier (2011) state that ‘the weight of the body of evidence, based on the combined weights of
individual pieces of evidence, may be used to express conﬁdence or uncertainty in the results’.
Weight of evidence assessment is deﬁned above as a process which determines the relative support
for possible answers to a scientiﬁc question. EFSA (2016a–c) deﬁnes uncertainty as ‘a general term
referring to all types of limitations in available knowledge that affect the range and probability of
possible answers to an assessment question’. Answers may refer to alternative hypotheses or
estimates, and probability is one way of expressing relative support for possible answers. Thus, the
weight of evidence conclusion for a question and the uncertainty of the answer can be expressed in
identical form: the range of possible answers and their relative degree of support or probability. This is
explicit in meta-analysis, an evidence integration method producing conclusions in the form of
estimates with conﬁdence intervals, which express uncertainty.
However, expression of uncertainty for the conclusion of the scientiﬁc assessment as a whole
should additionally include any uncertainties associated with the weight of evidence process itself. This
may include uncertainties regarding, for example, the selection of evidence, assessment of reliability,
relevance and consistency, and choice of weight of evidence methods. These should be taken into
account by uncertainty analysis following the weight of evidence assessment (as indicated in Figure 1
above), and may modify the range and probability of answers to some degree.
Consistent with this, each of the three basic considerations in the weight of evidence assessment
may be expressed in terms of uncertainty:
• the reliability of a piece or line of evidence can be expressed as the uncertainty of that
evidence itself (i.e. how different the evidence might be if the information comprising it was
correct);
• the relevance of a piece or line of evidence can be expressed as the uncertainty that would be
associated with extrapolating from fully reliable information, of the type provided by that
evidence, to its contribution to answering the weight of evidence question;
• limitations in consistency between pieces or lines of evidence add to uncertainty about the
answer to the weight of evidence question. In principle, different pieces or lines of evidence
for the same question should be consistent, if allowance is made for their reliability and
relevance (this is discussed further in Section 4.4).
Thus weight of evidence assessment could be regarded as contributing to uncertainty analysis,
addressing the part of uncertainty that relates to limitations in reliability, relevance and consistency of
the evidence. Uncertainty which is addressed in the weight of evidence assessment does not need to
be re-analysed in the uncertainty analysis, but may be added to (see Section 4.5).
Probability is not the only way to express relative support or uncertainty. It can also be expressed
qualitatively, and this is essential for any uncertainties or aspects of weight of evidence assessment
that cannot be quantiﬁed (see Section 5.10 of EFSA, 2016a–c). As explained above and by EFSA
(2016a–c), expressing the probability of possible answers is important for the conclusions of a scientiﬁc
assessment, but need not apply to earlier steps in the weight of evidence process.
2.7. Relation of weight of evidence assessment and variability
It is important also to consider how the weight of evidence assessment relates to variability.
Variability is deﬁned by EFSA (2016a–c) as ‘heterogeneity of values over time, space or different
members of a population, including stochastic variability and controllable variability’. Note that ‘values’
could refer to values on a quantitative scale, or to alternative qualitative descriptors, and that
‘population’ is not restricted to biological populations but may also refer to other entities (e.g.
variability in temperature at different points in time and space).
Variability is often important in a scientiﬁc assessment, e.g. variability in chemical occurrence in
food and consumption are important in chemical exposure assessment. This needs to be dealt with
when deﬁning the questions for assessment, such that they refer to speciﬁc descriptors or summaries
of the variable quantity, such as the average or 95th percentile exposure. If weight of evidence
assessment was used as part of the exposure assessment, for example to integrate occurrence data
from different countries, the reliability, relevance and consistency of the different pieces or lines of
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evidence regarding the variability of occurrence would be assessed. Thus, variability can be the subject
of a weight of evidence assessment, rather than a contributor to it.
Variability in data is a combination of real variability of the quantity being measured (e.g. between
individuals) and variability of the measurement process (measurement error, a form of uncertainty).
Variability in data due to measurement error should be taken into account when assessing reliability.
Variability between results reported by different studies might reﬂect differences in the reliability of
those studies or differences in their relevance for the assessment. Such differences may lead to
apparent inconsistencies in data that need to be considered when integrating evidence (Section 4.4).
3. Overview of qualitative and quantitative methods for weight of
evidence assessment
3.1. Examples of weight of evidence approaches
3.1.1. Classiﬁcation of weight of evidence approaches
Several reviews of weight of evidence approaches have been published, especially by Chapman
et al. (2002), Weed (2005), Linkov et al. (2009), Lorenz et al. (2013) and ANSES (2016).
Instead of conducting another review of weight of evidence approaches, the SC scrutinised the
existing reviews to identify approach(es), which could be useful for classifying weight of evidence
methods suitable for ecotoxicological assessments. A classiﬁcation proposed by Linkov et al. (2009)
has been taken as a starting point (with modiﬁcations, see below) as it covers a broad range of
methods with contrasting levels of complexity; it enables methods to be grouped according to whether
they are qualitative and/or quantitative; and it can also capture weight of evidence methods identiﬁed
in the more recent reviews. It is important to stress that the classiﬁcation here is illustrative rather
than prescriptive. Linkov et al. (2009) distinguish the following types of weight of evidence
assessment:
Listing evidence: Presentation of individual lines of evidence without attempt at integration
Best professional judgement: Qualitative integration of multiple lines of evidence
Causal criteria: A criteria-based methodology for determining cause and effect relationships
Logic: Standardised evaluation of individual lines of evidence based on qualitative logic models
Scoring: Quantitative integration of multiple lines of evidence using simple weighting or ranking
Indexing: Integration of lines of evidence into a single measure based on empirical models
Quantiﬁcation: Integrated assessment using formal decision analysis and statistical methods.
In the Linkov et al. (2009) classiﬁcation system, approaches are grouped by the degree to which
they are quantitative. The least quantitative approaches are categorised as ‘Listing evidence’, while the
most quantitative ones fall within the category ‘Quantiﬁcation’ and are based on statistical approaches
or on formal decision-analytical tools. Other categories correspond to intermediate situations.
The current guidance does not formally distinguish between the categories ‘listing evidence’ and
‘best professional judgement’. Linkov et al. (2009) suggest that approaches described as ‘listing
evidence’ do not attempt to integrate lines of evidence together. Rather, lines of evidence ‘are simply
presented, although the assessor will at times make claims that the weight of evidence assessment
points to speciﬁc conclusions’ (Linkov et al., 2009). In ‘listing evidence’, it is implicit that integration of
evidence must take place in order to reach conclusions, although the integration may not be based on
a formal method. ‘Listing evidence’ is therefore considered here as being synonymous with ‘best
professional judgement’ rather than being a separate category.
In addition, the current guidance groups together the Linkov et al. (2009) categories ‘Logic’,
‘Scoring’ and ‘Indexing’ as they are approaches involving rating which share many common
characteristics. These three categories are considered here as a single category named ‘Rating’. Thus,
the SC considers four categories of weight of evidence assessment methods: best professional
judgement, causal criteria, rating and quantiﬁcation. Examples of these approaches are listed below
for each category. Some of them cover all three basic steps of the general weight of evidence process,
while others are more speciﬁc and focus on one or two steps. Approaches restricted to problem
formulation were considered as outside the scope of this guidance, and are not included.
The SC does not aim to cover here all existing approaches, but rather to give a brief overview of
different types of approaches and to provide key references. Examples are brieﬂy presented in the
following sections (note that these are included only to illustrate the categories and are not intended
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as examples of best practice). Categories described in Sections 3.1.2–3.1.3 (best professional
judgement and causal criteria) are collectively referred to in this guidance as qualitative approaches.
Several criteria are then presented in Section 3.2 to help risk assessors to choose among weight of
evidence approaches. These approaches have been used in different EFSA scientiﬁc assessments (see
for example Annex C). Note that assessments may use a combination of more than one of these
categories.
3.1.2. Category ‘Best professional judgement’
In this category, no formal method is used for evidence integration. Instead, the listed pieces of
evidence are used to form a conclusion by professional opinion via a discussion of the ﬁndings. The
approaches of this category simply list pieces of evidence in text or in tables. The origin of the
evidence depends on the approach used for assembling evidence, for example:
• Several methods of evidence synthesis which do not involve quantitative integration could be
classiﬁed under this category. These include extensive literature searches (EFSA, 2010a;
Higgins and Green, 2011), systematic maps (CEE, 2016; James et al., 2016), and non-
quantitative systematic reviews (i.e. those lacking a quantitative data synthesis step) (EFSA,
2010a; Higgins and Green, 2011).
• Evidence can be directly provided by applicants in reports and/or datasets rather than being
selected by risk assessors.
Clear documentation of the discussion is important to ensure transparency in how decisions were
reached. Several examples are given in the review of Linkov et al. (2009), notably Staples et al.
(2004).
3.1.3. Category ‘Causal criteria’
Approaches of this category provide a structure based on explicit criteria to evaluate relationships
between cause and effect from one or several lines of evidence. The Bradford Hill considerations (Hill,
1965) are widely used, especially in epidemiology. They are often seen as the minimal conditions
needed to establish a causal relationship between two items, and are frequently used in
epidemiological studies to assess the extent of supporting evidence on causality. They are also used, in
modiﬁed form, to weight of evidence assessment in mode of action analysis (Meek et al., 2014).
Several variants have been proposed in the literature. For example, Becker et al. (2015) proposed a
template based on modiﬁed Bradford Hill considerations for weight of evidence assessment of adverse
outcome pathways.
3.1.4. Category ‘Rating’
This category includes a variety of frameworks that involve rating of evidence. Examples include
GRADE3 (Guyatt et al., 2011), WHO-IARC (IARC, 2006), WCRF/AICR (2007), OSHA (2016) and
guidance used to produce NTP Monographs (NTP, 2015; OHAT, 2015). Guidance to assess and
integrate evidence is based on several factors, often derived from the Bradford-Hill considerations.
However, ‘Rating’ builds on the approaches of the category ‘Causal criteria’ in that more guidance is
provided for appraising and integrating evidence.
These approaches usually relate to the second step of the weight of evidence process, including the
appraisal of individual studies and rating conﬁdence in the individual lines of evidence (e.g. ‘high
conﬁdence,’ ‘sufﬁcient evidence’). Some of them also provide tools based on a matrix for integrating
lines of evidence to reach hazard identiﬁcation conclusions (WHO-IARC, OHAT, OSHA (2016)). None of
these approaches use formal probabilistic techniques, but it is possible to combine application of the
structured framework guidance with a more quantitative presentation of conclusions.
Some of these approaches (e.g. GRADE) are designed to be ﬂexible for use in a variety of
disciplines and able to be applied under different time and resource constraints in situations
corresponding to different levels of urgency (Thayer and Sch€unemann, 2016).
In EFSA, the scheme presented in the ‘Guidance on a harmonised framework for pest risk
assessment and the identiﬁcation and evaluation of pest risk management options’ (EFSA, 2010a)
belongs to this category.
3 GRADE stands for Grading of Recommendations, Assessment, Development and Evaluation.
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3.1.5. Category ‘Quantiﬁcation’
This category covers a large diversity of approaches that can be used to integrate evidence into
lines of evidence and/or to integrate different lines of evidence in order to reach a general conclusion.
This category includes standard statistical models such as ﬁxed-effect and random-effect linear and
generalised linear models. These are commonly used for meta-analysis. A typical application is to
estimation of mean effect sizes, which can be interpreted as summary estimates of a quantity based
on statistical integration of evidence from multiple primary studies. These statistical models may also
be used for meta-regression to explain the variability between studies as a function of explanatory
variables, for example, population characteristics or study quality issues. They are able to describe
uncertainties through conﬁdence intervals and probability distributions. Other types of statistical
methods (e.g. Bayesian methods) are also useful for synthesising multiple sources of evidence.
In addition to statistical methods, other approaches have been proposed, especially machine
learning, in silico tools and multicriteria analysis. Linkov et al. (2015) consider that multicriteria
decision analysis can be used as a proxy for the Bayesian approach to weight of evidence assessment
when model formulation is restricted by data limitations.
When a quantitative model is used for weight of evidence assessment, several authors recommend
performing a sensitivity analysis to study the stability of the main conclusions to the model assumptions,
e.g. to the model equations, or to the parameter values (Borenstein et al., 2009; Linkov et al., 2011).
Examples of quantitative approaches and several key references are listed below:
• Statistical methods for integrating data provided by several studies sharing similar
characteristics (classic ﬁxed-effect and random-effect models used in meta-analysis, and
Bayesian hierarchical models). Many textbooks and methodological papers are available on
these methods, for examples Borenstein et al. (2009) on classic techniques, and Sutton and
Abrams (2001) and Higgins et al. (2015) on Bayesian methods in the context of meta-analysis.
• Statistical methods for integrating different types of studies in order to allow decisions based
on all available evidence and to analyse uncertainty (Small, 2008; Turner et al., 2009; Gosling
et al., 2013).
• Quantitative expert judgement including multicriteria decision analysis for integrating different
types of studies (Linkov et al., 2011, 2015).
• Machine learning techniques (Li and Ngom, 2015).
• In silico tools including QSAR, PBTK-TD (ECHA, 2016).
3.2. Choosing weight of evidence methods
A challenge when planning a weight of evidence assessment is to determine which assessment
method(s) to select, given the variety of different methods available. A single easy-to-use weight of
evidence method that covers all the basic steps of the weight of evidence process and enables
transparent quantiﬁcation of uncertainty may not be available. A pragmatic approach is therefore
recommended for identifying the most suitable method, or combination of methods, for the weight of
evidence assessment. A list of criteria for comparing weight of evidence methods is suggested in
Table 1, to assist in evaluating the relative strengths and weaknesses of the different methods. This
list is not exhaustive but based on discussions during the development of the current guidance; the
criteria have not been formally tested and are not intended to be prescriptive or mandatory, but are
intended to aid the justiﬁcation and selection of methods. The criteria may also be helpful for
transparently recording and reporting the decision-making process used for weight of evidence method
selection, in keeping with EFSA’s requirement for transparency in the conduct and reporting of
scientiﬁc assessments (EFSA, 2006).
As with any type of evidence synthesis, weight of evidence methods face a potential trade-off
between what would be ideal in terms of resource requirement (i.e. rapid, cheap, methods) and
scientiﬁc rigour (i.e. methods that transparently display uncertainty at all steps of the weight of
evidence process). Careful consideration will be needed early on in the planning process (in problem
formulation) to ensure that adequate resource (time, staff expertise) is available to achieve the desired
level of scientiﬁc rigour. In EFSA weight of evidence assessments which have prespeciﬁed and ﬁxed
resources, the criteria in Table 1 could be used to judge the optimal scientiﬁc rigour that could be
achieved within the available resources. Alternatively, if resource availability for a weight of evidence
assessment is negotiable, or if a weight of evidence assessment is at a preliminary scoping phase,
these criteria may be helpful for estimating the resource needs for the assessment.
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The criteria in Table 1 should be considered together by assessors when planning weight of
evidence assessment. This is because the strengths and weaknesses of weight of evidence methods
are multidimensional, and individual criteria alone may not be able to capture important trade-offs,
e.g. between resource availability and scientiﬁc rigour. Note that the criteria do not necessarily have
equal importance: their relative importance may be discussed on a case-by-case basis when planning
each weight of evidence assessment. The criteria in Table 1 are not exhaustive. Other criteria which
may be useful include the strength and scope of the theoretical basis for a method and the extent to
which the output of the method is in a form which can be tested.
4. Practical guidance for conducting weight of evidence assessment
This section contains practical guidance for applying weight of evidence approaches within EFSA
scientiﬁc assessments. Assessors should choose the speciﬁc approaches that are best suited to the
needs, time/resources available and context of their assessments.
Table 1: Criteria for assessing the relative strengths and weaknesses of weight of evidence methods
Criterion Key considerations
Time needed Weight of evidence methods that can be conducted quickly would be preferable
where urgent weight of evidence assessments are required. However, rapid
methods risk sacriﬁcing scientiﬁc rigour. When estimating the time required for a
particular weight of evidence method, consideration should be given to the
availability of expertise, since this could inﬂuence the time required for a weight of
evidence assessment
Amount and nature of
the evidence
The amount of evidence and its type (e.g. experimental, expert knowledge,
surveys, qualitative, quantitative or combination) may affect which methods of
weight of evidence assessment could be applied: the choice among these would
then be determined by other criteria in this table. The similarity of the available
studies may also be relevant, e.g. in deciding whether meta-analysis is an option
Availability of guidance Guidance on the weight of evidence method should be readily available in the
public domain and, ideally, should be endorsed, e.g. through peer-review and/or
wide acceptance. Guidance should document the rationale of the method, the full
process, and how to interpret the results. Ideally, access to help and support
facilities should be readily available (e.g. any relevant tools such as tutorials,
software programs or modules). Availability of guidance is important both for the
conduct and the critical appraisal of weight of evidence assessments. Weight of
evidence methods that lack adequate guidance would rate poorly on this criterion
Expertise needed Weight of evidence methods are likely to vary in the level of technical skill required
to conduct them. Some quantitative methods, for example, may require speciﬁc
skills in statistics and/or programming. The expertise requirement should be
considered in relation to availability of expertise and tools and, if necessary,
whether available resources would support the outsourcing of expertise or
provision of training. The level of expertise required has implications both for the
conduct and the critical appraisal of weight of evidence assessments
Transparency and
reproducibility
Transparency and reproducibility are fundamental principles required by EFSA in its
scientiﬁc assessments. Transparency should apply to all parts of the weight of
evidence method, meaning that it should be possible to follow clearly how the input
data for the assessment are analysed to produce the conclusions. Reproducibility is
deﬁned such that consistent results should be expected if the same method were
to be repeated using the same input data (but note that results are unlikely to be
identical, dependent on the degree to which expert opinion is involved)
Variability and
uncertainty
Weight of evidence methods should, ideally, explicitly report and analyse both
variability and uncertainty at all steps of the assessment, and propagate them
appropriately through the assessment. Quantitative expression of variability and
uncertainty is preferable to qualitative expression. Careful consideration may be
needed to ensure that the weight of evidence method can include all relevant
sources of variability and uncertainty
Ease of understanding
for assessors and risk
managers
Weight of evidence methods are likely to vary in how easy they are to understand
by non-specialists, and this may be related to the expertise needed, as well as the
availability of adequate guidance. It will be beneﬁcial if the principles of the
methods chosen can be readily understood by assessors and risk managers
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Three types of assessment are distinguished, which require different approaches:
• assessments where the approach to integrating evidence is fully speciﬁed in a standardised
assessment procedure;
• case-speciﬁc assessments, where there is no pre-speciﬁed procedure and assessors need to
choose and apply approaches on a case-by-case basis;
• emergency procedures, where the choice of approach is constrained by unusually severe
limitations on time and resources.
Standardised assessment procedures have been established in many areas of EFSA’s work,
especially for regulated products. Standardised procedures are generally deﬁned in documents, e.g. EU
regulations or EFSA guidance documents. They specify what questions should be addressed, what
evidence is required, and what methods of assessment should be applied to it. They generally include
standardised elements that are assumed to provide adequate cover for uncertainty (EFSA, 2016a–c).
Where a standard assessment involves questions that require integration of evidence, the methods
for doing this will be speciﬁed in the standard procedure. For example, in human health risk
assessment of chemicals in food, the outcome may often be based on one of the available studies,
which is considered to provide the highest level of protection for the consumer. While not generally
thought of as weight of evidence, this is a procedure for integration which, after considering all the
evidence, in effect gives all the weight to a single study (sometimes referred to as the critical study).
In assessments following a standardised procedure, the default approach should be to integrate
evidence using the methods as speciﬁed by the procedure. If the methods are speciﬁed in detail, they
may be sufﬁcient to conduct the assessment without further guidance; where the methods are not
fully speciﬁed, the assessor may beneﬁt from the guidance in Sections 4.1–4.6. If an assessment that
would normally be addressed by a standard procedure includes weight of evidence issues that are not
adequately addressed by the standard procedure, a case-speciﬁc approach will be needed for that part
of the assessment, following the guidance in Sections 4.1–4.6.
In case-speciﬁc assessments, for which there is no standard procedure, evidence integration
will need to be conducted case-by-case, following the guidance in Sections 4.1–4.6.
Emergency assessments are required in situations where there are exceptional limitations on time
and resources. If an emergency assessment involves scientiﬁc questions that require integration of
evidence, assessors should ﬁrst consider whether any standard procedure exists that can be applied within
the time and resources available. If not, then the assessor should conduct a case-speciﬁc assessment,
choosing options from Sections 4.1–4.6 that are compatible with the time and resources available.
In some cases, the literature available for an assessment includes previous reviews or
assessments of a similar question, which themselves involve weight of evidence assessment.
Ideally, assessors should access and evaluate the original evidence used in the previous assessments,
rather than treating the outcomes of previous assessments as evidence per se. However, when time
and resources are too limited to access all the original evidence, then it may be justiﬁable to make use
of the previous assessments in the new assessment. If this is done, it will be essential to take account
of any differences between the questions addressed in the previous and new assessments, and of any
differences or shortcomings in the criteria and assessment methodology that were used, and to
document these considerations transparently.
4.1. Deﬁne the questions for weight of evidence assessment
A single assessment may comprise one or more scientiﬁc questions and none, some or all of those
questions may require weight of evidence assessment. Interpreting the questions posed by the Terms
of Reference, and deciding whether to subdivide them, is part of the ﬁrst stage of scientiﬁc
assessment, often referred to as problem formulation. General guidance on problem formulation for
EFSA’s scientiﬁc assessments is provided in other documents (EFSA, 2006, 2015a,b), and the need to
ensure questions are well-deﬁned is further discussed by EFSA (2016a–c). Weight of evidence
assessment does not involve any additional requirements or considerations for specifying the questions
for assessment, so the reader is referred to the documents referred to above for details.
Problem formulation also includes planning the strategy and methods for assessment (EFSA, 2015a,
b). As part of this, the assessors should identify which of the questions in the assessment will require
integration of evidence and therefore the use of weight of evidence approaches.
The output of problem formulation should therefore include a list of the questions. Each question
that requires weight of evidence assessment should then be addressed by applying the basic steps
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described in the three following subsections. When the assessment involves a hierarchy of questions,
start with the questions at the lowest level of the hierarchy, as the conclusions of these will inform
lines of evidence for higher questions. It is sometimes necessary to return to and revise the problem
formulation later, if additional questions are identiﬁed in the course of the assessment.
4.2. Assemble the evidence
This is the ﬁrst of the three basic steps of weight of evidence assessment for an individual question
(see Section 2.4). Guidance for this and the following two steps is provided as a series of numbered
(sub)steps, which may be considered in sequence. For every step, assessors should choose
approaches that are appropriate to the needs and context of the assessment in hand, including any
limitations on time and resources.
1) Identify potentially relevant evidence. In some EFSA assessments, the evidence to be
used is deﬁned by regulations or guidance, and/or submitted by applicants. This applies
especially in standard assessment procedures. When data gaps (absence of required data)
are identiﬁed, it may be possible to mitigate their effect using other evidence, for example
by read-across, if this is permitted by the relevant regulations or guidance. In non-standard
(case-speciﬁc) assessments, the assessors deﬁne the strategy and criteria for identifying and
accessing potentially relevant evidence. Procedures for this, with varying degrees of
formality, are described in EFSA guidance on extensive literature searching and systematic
review (e.g. EFSA, 2010a, 2015b), which is designed to increase coverage and reduce
potential biases in evidence gathering.
2) Select evidence to include in the weight of evidence assessment. In principle, all
evidence identiﬁed as potentially relevant in step 1 should be taken into account, but
limitations on time and resources may require the assessment to focus primarily on the
most relevant and/or most reliable evidence. This subset of evidence may be identiﬁed by
ﬁltering or screening using appropriate criteria for relevance and/or reliability (EFSA, 2010b,
2015b). Evidence that was considered potentially relevant but not included should be
retained separately, for example as a list of references or archive of documents, so that the
impact of excluding it can be considered as part of uncertainty analysis (below).
3) Group the evidence into lines of evidence, i.e. subsets of evidence which the assessors
ﬁnd useful to distinguish when conducting the assessment. There are no ﬁxed rules for how
to form lines of evidence, but it may be helpful to distinguish those which are standalone
and those that are complementary (Section 2.1). If the lines of evidence are
complementary, they may be grouped according to the contribution they make to answer
the question (e.g. exposure, hazard, etc.). Standalone lines of evidence may comprise
evidence on the same aspect of the assessment but generated by different methods (e.g.
different study types), with different subjects (e.g. species, chemicals, etc.) and in different
conditions. This will tend to group evidence that has similar relevance and/or reliability. The
lines of evidence and the rationale for constructing them should be documented, identifying
which are standalone and which are complementary.
4.3. Weigh the evidence
Four broad categories of methods for weight of evidence assessment are presented in Section 3,
together with suggestions for choosing between them: best professional judgement, causal criteria,
rating and quantitative methods. Assessors should ﬁrst consider the possibility of using quantitative
methods because an appropriate and well-conducted quantitative analysis will generally be more
rigorous than other methods. For example, when it is possible and appropriate to combine multiple
studies by meta-analysis, this will be more rigorous than integrating them by expert judgement.
However, there are two important caveats to this. First, quantitative methods may not be appropriate
for various reasons, e.g. not applicable to the nature, quantity or heterogeneity of the evidence to be
integrated, not practical within the time and resources available, etc. Second, quantitative methods
may not address all the considerations that are relevant for weighing the evidence. For example,
common approaches to meta-analysis only capture those aspects of reliability and consistency that are
represented in the variability of the data, although some forms of meta-analysis can also take account
of relevance and additional aspects of reliability (e.g. Turner et al., 2009).
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Therefore, the approach proposed below is to check ﬁrst whether quantitative methods are
practical and appropriate, and then complement them with qualitative methods (categories to ensure
all relevant considerations are addressed). When quantitative methods are not practical or appropriate,
only qualitative methods can be used. However, assessors should start by deciding what considerations
are relevant for weighing the evidence, as this may have implications for the choice of methods.
When there are data gaps, due to the absence of data that are normally required, the weight that
those data would have had will be absent and this will be taken into account when the available
evidence is integrated (see Section 4.3).
1) Decide what considerations are relevant for weighing the evidence. The general
considerations for weighing evidence are reliability, relevance and consistency, as explained and
deﬁned in Section 2.5. Assessors may choose to work with these three basic considerations, or
use more speciﬁc criteria appropriate to their area of work, especially if these have already been
established in guidance or the scientiﬁc literature. If using pre-established criteria, assessors
should check that they cover all aspects of reliability, relevance and consistency that are relevant
for the assessment in hand, and deﬁne any additional criteria that are needed.
a) Reliability is the extent to which the information comprising a piece or line of evidence
is correct. It may be assessed by considering the uncertainty of the evidence, i.e. how
different it might be if the information comprising it was correct. Everything that
contributes to that uncertainty should be included when assessing reliability.
b) Relevance is the contribution a piece or line of evidence would make to answer a
speciﬁed weight of evidence question, if the information comprising the evidence were
fully reliable. Everything that contributes to the need for extrapolation, and its
uncertainty, should be included when assessing relevance.
i) For a standalone line of evidence, consideration of relevance involves thinking about
how well that evidence would answer the question, if the information comprising it
were fully reliable. How much extrapolation is involved, between the subjects and
conditions the evidence relates to and those relevant for the question and how
uncertain is that?
ii) For a complementary line of evidence, consideration of relevance involves identifying
what that evidence contributes to the conceptual model or argument for answering
the question, and considering what extrapolation is required to provide that
contribution.
c) Consistency should be considered when integrating evidence (below).
2) Decide on the method(s) to be used for weighing and integrating the evidence.
Refer to the categories and criteria in Section 3. Some of the methods for weighing evidence
also perform the integration step (e.g. meta-analysis), or limit the choice of methods for
integration, so both steps should be considered when choosing between methods. The choice
of methods may also be affected by whether the lines of evidence are standalone or
complementary. For example, meta-analysis can be used to integrate standalone lines of
evidence, whereas complementary lines of evidence require a quantitative model of the
relationships between the lines of evidence and the answer to the question (e.g. the
relationships between exposure, hazard and risk).
a) Consider whether quantitative methods are practical and appropriate for the
needs and context of the assessment. If it is decided to use a quantitative method,
identify which aspects of reliability, relevance and consistency it will address, and which it
will not.
b) Choose one or more qualitative methods to address those aspects of
reliability, relevance and consistency that are not treated quantitatively. This
could include methods from one or more of the non-quantitative categories presented in
Section 3.
c) Check that the chosen methods (quantitative and/or qualitative) address all
pertinent aspects of reliability, relevance and consistency (identiﬁed in step 1
above).
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d) If more than one method is chosen for weighing evidence, consider whether
their results can be combined directly when integrating the evidence. Some
methods are capable of incorporating the outputs of other methods: e.g. Doi (2014) has
developed methods for incorporating quality scores into meta-analysis, while Turner et al.
(2009) have proposed methods for incorporating quantitative expert judgements about
the effects of study limitations (which may include reliability and relevance) into meta-
analysis. Such methods may be used, if they are appropriate and practical for the needs
and context of the assessment.
3) Apply the chosen methods for weighing the evidence and summarise the results in
a form that is helpful for integration. Weighing will often be conducted at the level of
individual pieces of evidence. Alternatively, pieces of evidence within the same line of evidence
could be weighed collectively. The latter option may be quicker when time is limited but
requires an implicit integration of the pieces within the line of evidence, so is less transparent
and may be more challenging for the assessors to perform (because it requires weighing and
integrating simultaneously).
When more than one method of weighing is used (e.g. a quantitative method combined with a
qualitative method), it is recommended to ﬁnd a way of presenting the results together in a
concise tabular or graphical summary. For example, estimates and conﬁdence intervals from
quantitative methods can be plotted on a graph alongside symbols or text showing the results
of qualitative methods (e.g. EFSA, 2015a, 2016a). This provides a useful overview of the
evidence, which may be helpful for the assessors in the integration step and also for others,
who read the ﬁnished assessment.
4.4. Integrate the evidence
In this step, the evidence is integrated to arrive at the conclusion, taking account of the reliability
and relevance of the evidence, assessed in the preceding step, and also the consistency of the
evidence. To reach a conclusion on the weight of evidence question, integration is necessary both
within and between lines of evidence. When there are data gaps, due to the absence of data that are
normally required, the absence of the weight those data would have contributed will be reﬂected in
the outcome of the integration process. When appropriate, the effect of this may be mitigated by the
contributions of other evidence (e.g. read-across), or taken into account by use of assessment factors
(which should themselves be evidence-based).
1) Consider the conceptual model for integrating the evidence. Integration always
involves a conceptual model, even if this is not made explicit. Integrating standalone lines of
evidence requires a conceptual model of how evidence of differing weight is combined.
Integrating complementary lines of evidence additionally requires a conceptual model of the
contributions made by the different lines of evidence and how they combine to answer the
question. In both cases, it is important to take account of any dependencies between different
pieces and/or lines of evidence. Dependencies can have an important impact on how evidence
should be integrated (see point 3 below).
Assessors may ﬁnd it helpful to make the conceptual model explicit, e.g. as a ﬂow chart or list
of logical steps. This should help assessors to take appropriate account of the relationships
and dependencies between pieces and lines of evidence, and between the evidence and the
question being assessed, both when the integration of evidence is done by expert judgement
and when it is done using a quantitative model. Making the conceptual model explicit also
contributes importantly to the transparency of the assessment.
2) Assess the consistency of the evidence. Consistency is the extent to which the
contributions of different pieces or lines of evidence are compatible (Section 2.5). Limitations
in consistency arise in part from limitations in the relevance and reliability of different pieces or
lines of evidence. If a question is well-deﬁned, only a single correct answer should be possible,
and any apparent inconsistencies in the evidence should be explicable in terms of differences
in reliability and/or relevance. Assessors should not, however, simply conclude that inconsistent
evidence is unreliable or irrelevant. Rather, assessors should consider whether, after taking
differences in reliability and relevance into account, the pieces or lines of evidence still appear
inconsistent. If so, this may imply the presence of additional limitations in relevance and
reliability, beyond those already taken into account, or limitations in the conceptual model for
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integrating the evidence. Alternatively, it may imply there is more than one possible answer to
the question, in which case the question may need to be more precisely deﬁned or split into
two or more separate questions. Any remaining inconsistency should be considered as part of
the uncertainty affecting the weight of evidence conclusion.
3) Apply the method(s) chosen for integrating the evidence (the methods chosen in step
2 of Section 4.3, above). As already mentioned, one or more methods may be used, from one
or more of the categories of methods described in Section 3.
It may often be helpful to approach integration hierarchically, starting with evidence that is
more closely related. This is one of the reasons for grouping evidence into lines: ﬁrst, pieces of
evidence are integrated within each line of evidence, and then different lines of evidence are
integrated. When integrating evidence, it is important to take account of dependencies. The
result of integrating two dependent pieces or lines of evidence will have more or less weight
than had they been judged independent (see EFSA, 2016a–c for further discussion of
dependency).
4) Develop the conclusion for the weight of evidence assessment. If there is no single
method that can take into account all the pertinent aspects of reliability, relevance and
consistency, it will be necessary to integrate the results of the different methods by expert
judgement. This may be done within the process for reaching a conclusion, as follows:
a) Summarise all the results up to this point in a concise tabular or graphical
format. This should comprise all the results of weighing the evidence, as in step 3 of
Section 4.3, together with the results of any integration that has been done (e.g.
integrated estimates and conﬁdence intervals from meta-analysis or integrated scores
from scoring methods).
b) Deﬁne how the conclusion of the weight of evidence assessment (range of
possible answers and their relative support) will be expressed. The range of
answers may be expressed on an appropriate quantitative scale or as alternative
qualitative statements or propositions. Relative support for the possible answers may be
expressed quantitatively, e.g. as probabilities or qualitatively.
i) When weight of evidence assessment directly addresses the conclusion of a scientiﬁc
assessment, the range of possible answers and how probable they are should be
expressed quantitatively if possible. Any considerations that cannot be included in the
quantitative expression imply that the conclusion will be subject to unquantiﬁed
uncertainties, which should be described qualitatively (see EFSA, 2016a–c). If no
quantitative expression is possible, this implies that each probability could be
anywhere between 0% and 100%, and the assessor should consider whether the
evidence supports any conclusion at all (see also Sections 5.10 and 5.11 of EFSA,
2016a–c).
ii) When weight of evidence assessment addresses an intermediate question in a larger
assessment, the range of answers and their relative support may expressed either
qualitatively or quantitatively, depending what is convenient for use in subsequent
steps of the assessment. One method could be taken as the primary method of
integration, for use in subsequent steps of the assessment, and additional
considerations (not covered by the primary method) could be carried over to the
uncertainty analysis at the end of the scientiﬁc assessment as a whole. For example,
if meta-analysis was used to integrate occurrence data in a chemical risk assessment,
the output of the meta-analysis could be used in subsequent steps of exposure and
risk assessment. Any other considerations regarding the quality and relevance of the
occurrence data and the assumptions of the meta-analysis would be addressed as
part of combined uncertainty at the end of the risk assessment (EFSA, 2016a–c,
Section 12).
c) Where expert judgement is required, use an appropriate procedure for this.
Expert judgement should always be careful, reasoned, evidence-based and transparently
documented. This may be achieved through formal expert knowledge elicitation (EFSA,
2014a), or semiformal expert knowledge elicitation or expert discussion (EFSA, 2016a–c).
The cited documents focus on eliciting distributions for quantitative parameters, but the
underlying principles can be applied also to eliciting probabilities for alternative answers
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to a qualitative question. Assessors should choose a procedure that is appropriate for the
needs, timeframe and context of their assessment. For example, if the judgement is likely
to be critical for decision-making, that would be a reason for more formal methodology, if
time and resources allow.
4.5. Uncertainty and inﬂuence analysis
All EFSA scientiﬁc assessments must include consideration of uncertainties, reporting clearly and
unambiguously what sources of uncertainty have been identiﬁed and what their impact on the
assessment outcome is. It is recommended that the combined impact of as many as possible of the
identiﬁed uncertainties be expressed quantitatively, in terms of the range and probability of possible
answers to the assessment question, and that any uncertainties that cannot be included in this should
be described qualitatively (EFSA, 2016a–c). These recommendations apply to weight of evidence
approaches, as well as other types of scientiﬁc assessment.
Weight of evidence assessment contributes to uncertainty analysis, as explained in Section 2.6.
However, weight of evidence conclusions expressed as the range of possible answers and their relative
support (e.g. an estimate and conﬁdence interval from a meta-analysis) may not incorporate all the
uncertainty affecting the weight of evidence assessment. First, the assessors may have omitted some
considerations regarding the evidence from the integration process, leaving them to be addressed in
the uncertainty analysis, as described in step 4b.ii. of Section 4.4. Second, there will often be
additional uncertainties associated with the identiﬁcation of evidence (including the choice of search
criteria), the impact of any potentially relevant evidence that was excluded from detailed assessment,
and the choice and implementation of methods for assembling, weighing and integrating data. This
includes ‘uncertainties in the judgement used’ in weight of evidence assessment (SCENIHR, 2012).
Assessors should systematically document all identiﬁable uncertainties affecting the weight of evidence
assessment, and take them into account in the assessment of combined uncertainty for the overall
scientiﬁc assessment (EFSA, 2016a–c, Section 12).
Inﬂuence analysis or sensitivity analysis is an optional part of scientiﬁc assessment (EFSA, 2016a–c).
It can be valuable in identifying which sources of uncertainty contribute most to the uncertainty of
assessment conclusions, and hence in targeting reﬁnement of the assessment when this is required.
When applied to assessments that include weight of evidence approaches, this could help decide
whether and where to reﬁne the weight of evidence assessment (see below). In meta-analysis, it is
good practice to study the inﬂuence of individual primary studies on the effect size estimates (e.g.
leverage plots, jack-knife procedure) and to study the impact of the modelling approach (e.g. random
effect model vs. ﬁxed effect model). In addition, meta-regression has been recommended to study the
sensitivity of the effect size estimates to explanatory factors related to the study characteristics. In case
of heterogeneity in the results of primary studies this may support identiﬁcation of major sources of
uncertainties and variability. Sensitivity analysis was also applied with other weight of evidence
approaches, especially with quantitative multicriteria analysis. For example, the last step of the
quantitative multicriteria analysis framework described by Linkov et al. (2011) explicitly deals with
sensitivity analysis. It is useful to explore analogies between these formal approaches for inﬂuence
analysis and similar approaches applicable in less formal methods for evidence integration. For
example, it can be recommended to study the effect of leaving out individual lines of evidence or, if
applicable, individual pieces (e.g. primary studies) on the weight of evidence conclusions. Likewise,
alternative methods for evidence integrating could be used and their inﬂuence on the weight of
evidence conclusion be demonstrated.
4.6. Iterative reﬁnement of the assessment
Iterative reﬁnement is an option in any type of scientiﬁc assessment. It is generally aimed either at
reducing uncertainty or improving the characterisation of uncertainty, in those areas of the assessment
that contribute most to the uncertainty of the assessment conclusions as identiﬁed by inﬂuence analysis
or sensitivity analysis (EFSA, 2016a–c). In general, assessment should start at a level of reﬁnement the
assessors consider appropriate to the needs and context of the assessment, and then be reﬁned as far
as is necessary to inform decision-making or until the agreed time and resources are expended.
When reﬁnement is needed in parts of an assessment where weight of evidence approaches are
used, this can be achieved by returning to earlier steps of the process (illustrated in Figure 1),
depending on what contributes best to reﬁning the assessment. In some cases, it may be sufﬁcient to
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reﬁne one or more of the basic steps of the weight of evidence assessment, whereas in other cases it
may be beneﬁcial to return to problem formulation and reformulate the questions to be addressed. For
example, if a question involving complementary lines of evidence contributed signiﬁcantly to overall
uncertainty, consideration could be given to further subdividing the question, addressing each
complementary part as a separate subquestion, and then combining their conclusions (with the option
of using a quantitative model).
5. Reporting weight of evidence assessment
If the weight of evidence assessment has been conducted following a standardised procedure
previously established for use in this area of EFSA’s work, the weight of evidence assessment may be
reported in the manner that is normal for that standardised procedure, provided this is transparent.
The standardised procedure should be referenced and its applicability to the case in hand should be
explained if it is not self-evident.
All other weight of evidence assessments should be reported as described below, although the level
of detail may be reduced due to time constraints in emergency assessments.
Reporting should be consistent with EFSA’s general principles regarding transparency (EFSA, 2006,
2009) and reporting (EFSA, 2014a, 2015b). In a weight of evidence assessment, this should include
justifying the choice of methods used, documenting all steps of the procedure in sufﬁcient detail for them
to be repeated, and making clear where and how expert judgement has been used. Where the assessment
used methods that are already described in other documents, it is sufﬁcient to refer to those. Reporting
should also include referencing and, if appropriate, listing or summarising all evidence considered,
identifying any evidence that was excluded; detailed reporting of the conclusions; and sufﬁcient
information on intermediate results for readers to understand how the conclusions were reached.
Weight of evidence assessment is part of the wider process of scientiﬁc assessment, as illustrated
earlier in Figure 1. Guidance on reporting other parts of the wider procedure, including evidence
review, problem formulation and uncertainty analysis, is provided elsewhere (e.g. EFSA, 2014b, 2015b,
2016a–c). This section focusses on the reporting for the three basic steps of weight of evidence
assessment: assembling the evidence, weighing the evidence and integrating the evidence. These
steps should be reported separately for each scientiﬁc question or subquestion that is addressed.
To aid transparency and accessibility for readers it may be useful to summarise weight of evidence
assessment in a tabular form. A suggested format is shown in Table 2. If a tabular format is not used,
then all the information listed in Table 2 must be included in the assessment report, in a location and
format that can easily be located by the reader (e.g. identiﬁable from section headings in the table of
contents). If the information is presented in tabular form, it should be concise (ideally not more than 1
page per table) and refer the reader to the text of the opinion for details.
Table 2: Optional tabular format for summarising weight of evidence assessment
Question Insert text of question here
Assemble the
evidence
Select evidence Brieﬂy summarise the methods used to search, select and extract the
evidence (see Note 1)
Lines of evidence List the line(s) of evidence into which the evidence were assembled for
assessment and identify any that are missing (see Note 2)
Weigh the
evidence
Methods Brieﬂy summarise the method(s) used to weigh the pieces and lines of
evidence (see Note 3)
Results Give a reference to the section of the assessment where the results of
weighing the pieces and lines of evidence are presented (see Note 4)
Integrate the
evidence
Methods Brieﬂy summarise the methods used to integrate the pieces and lines of
evidence (see Note 5)
Results State the conclusions of integrating the evidence for this question (see
Note 6)
Italic descriptions are for guidance only and should be deleted once the table is completed.
Notes cited in the table are presented below.
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• If the weight of evidence assessment directly addresses the conclusion of a scientiﬁc
assessment, results of weighing and integration that have been conducted by different
methods (e.g. a combination of qualitative and quantitative methods), should integrated into a
single conclusion on the relative support for different answers to the question, and expressed
quantitatively to the extent that is possible. Any considerations that remain unquantiﬁed should
be described qualitatively.
• If the weight of evidence assessment addresses an intermediate question in a larger scientiﬁc
assessment, results of weighing and integration that were conducted by different methods
may be expressed either qualitatively or quantitatively. They may either integrated into a single
conclusion here, or carried forward separately to later stages of the scientiﬁc assessment.
6. Way forward and recommendations
This guidance document is intended to guide EFSA Panels and staff on the use of the weight of
evidence approach in scientiﬁc assessments. It provides a ﬂexible framework that must be used in all
areas within EFSA’s remit, within which assessors should apply those methods which most
appropriately ﬁt the purpose of their individual assessment.
This guidance is intentionally and necessarily a general framework. However, the SC believes that
the principles and process are clear enough for EFSA Panels to apply them in their respective areas of
work. Where appropriate, this could lead to relevant approaches being incorporated in area-speciﬁc
guidance documents.
EFSA Panels and Units must ensure that their existing approaches to weight of evidence
assessment are in line with the unconditional requirements of the current guidance document
(Section 1.5). In particular, they should consider:
• whether all aspects of reliability, relevance and consistency that are pertinent in their area of
work are addressed,
• how to ensure the transparency of weight of evidence assessments.
It is further recommended that:
• EFSA identify areas of its work where a formalised weight of evidence assessment is especially
needed and initiate further work to apply suitable approaches from this guidance in those
areas. This might include, for example, the integration of different types of evidence in
chemical risk assessment, including in vivo, in vitro, in silico, omics, PBPK modelling as well as
the Mode of Action and Adverse Outcome Pathway concepts.
• EFSA identify speciﬁc weight of evidence approaches that may provide added value in EFSA’s
work (especially quantitative methods, e.g. meta-analysis) and consider whether further
guidance or training on them would facilitate uptake.
• EFSA should explore how to apply weight of evidence approaches in rapid scientiﬁc
assessments, where time and resources are limited.
Notes to Table 2:
Note 1. The summary of the methods used to search, select and extract the evidence should include, for example whether an
extensive literature search or systematic review was conducted, and whether any of the evidence was obtained by expert
elicitation and if so by which method.
Note 2. When listing the lines of evidence, give enough information for the reader to understand what they contain and how
they differ. Present them as numbered bullets for ease of reference. State whether the lines of evidence are complementary, or
standalone, or a mixture of both (see Section 2.1). Identify lines of evidence that were generated by (are conclusions from)
preceding weight of evidence questions (if any). Also, identify any lines of evidence that are required (e.g. by legislation or
guidance documents) but missing, i.e. data gaps.
Note 3. When summarising the method(s) used to weigh the pieces and lines of evidence, give enough information to make
clear the type of method involved (see types of method in Section 3). If weighing and integration was done in preceding
subquestions, refer the reader to where that is described. Refer the reader to the sections of the assessment where details of
each method are provided.
Note 4. The detailed results of weighing the evidence must be presented together, in an appropriate part of the assessment
report, in a format that helps the reader to compare the results for the different pieces and lines of evidence (e.g. a tabular
listing). If they can be summarised brieﬂy, include them in Table 2.
Note 5. Brieﬂy summarise the methods used to integrate the pieces and lines of evidence, giving enough information to make
clear the type of method involved (see types of method in Section 3 of Guidance).
Note 6. State the conclusion of integrating the evidence for this question in a form that expresses the range of possible answers
and their relative support.
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In implementing all the aforementioned recommendations, it is suggested that EFSA continues to
collaborate at the European and international level to harmonise developments in this area.
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Glossary and Abbreviations
Assembling the
evidence
The ﬁrst of three basic steps of weight of evidence assessment, as
proposed in this guidance. Includes identiﬁcation of potentially relevant
evidence, selection of evidence to include in the weight of evidence
assessment, and grouping the evidence into lines of evidence (see
Sections 2.4 and 4.2)
Best professional
judgement
A category of weight of evidence assessment methods involving qualitative
listing and qualitative integration of multiple pieces or lines of evidence (see
Section 3.1).
Case-speciﬁc
assessment
Case-speciﬁc assessments, where there is no pre-speciﬁed procedure and
assessors need to choose and apply weight of evidence approaches on a
case-by-case basis (see also EFSA, 2016a–c and Section 4).
Causal criteria A category of weight of evidence assessment methods based on criteria for
determining cause and effect relationships (see Section 3.1).
Complementary line of
evidence
A line of evidence which can only answer a question or subquestion when it
is combined with other line(s) of evidence (see Section 2.1).
Conceptual model Deﬁned by EFSA (2016b) in the context of environmental risk assessment
as ‘Step of the environmental risk assessment problem formulation phase
describing and modelling scenarios and pathways on how the use of a
regulated product may cause harm to a speciﬁc protection goal’. A form of
conceptual framework, which is deﬁned by Prometheus (EFSA, 2015a,b) as
‘The context of the assessment; all sub-question(s) that must be answered;
and how they combine in the overall assessment’. In the present guidance,
conceptual model refers to a qualitative description or diagram showing
how pieces and lines of evidence combine to answer a question or
subquestion, as well as any relationships or dependencies between the
pieces and lines of evidence. The conceptual model could be presented as,
for example, a ﬂow chart or list of logical steps (see Section 4.4).
Consistency The extent to which the contributions of different pieces or lines of
evidence to answering the speciﬁed question are compatible (see
Section 2.5).
Emergency assessment Emergency procedures, where the choice of approach is constrained by
unusually severe limitations on time and resources (see also EFSA, 2016a–c
and Section 4).
Estimate A calculation or judgement of the approximate value, number, quantity, or
extent of something (adapted from Oxford Dictionaries, 2017). Some
weight of evidence questions refer to estimates, while others refer to
hypotheses (see Section 2.1).
Evidence Information that is relevant for assessing the answer to a speciﬁed
question. In PROMETHEUS, a piece of evidence for an assessment is
deﬁned as data (information) that is deemed relevant for the speciﬁc
objectives of the assessment (EFSA, 2015b). In this Guidance, this is
expanded to all potentially relevant information, i.e. all evidence identiﬁed
by the initial search process, to recognise that the assessment of relevance
in the search process is necessarily a preliminary one (e.g. based on
keywords and titles alone). ‘Evidence’ can refer to a single piece of
potentially relevant information or to multiple pieces (see Section 2.1).
Expert judgement EFSA (2014a–d) deﬁnes an expert as a knowledgeable, skilled or trained
person. An expert judgement is a judgement made by an expert about a
question or consideration in the domain in which they are expert. Such
judgements may be qualitative or quantitative, but should always be
careful, reasoned, evidence-based and transparently documented (see
Section 4.4).
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GRADE An approach for grading the quality of evidence and the strength of
recommendations in environmental and occupational health, proposed and
developed by the Grading of Recommendations, Assessment, Development
and Evaluation (GRADE) Working Group (see Morgan et al., 2016).
Hypothesis One type of framing for weight of evidence questions. Deﬁned by Suter
(2016) as a proposition proposed to be a potential explanation of a
phenomenon or a potential outcome of a phenomenon. Some weight of
evidence questions refer to hypotheses, while others refer to estimates (see
Section 2.1).
Inﬂuence analysis A study of possible change in the assessment output resulting not just from
uncertainties about inputs to the assessment but also from uncertainties
about choices made in the assessment (EFSA, 2016a–c). See Section 4.6.
Integrating the evidence The third of three basic steps of weight of evidence assessment, as
proposed in this guidance. Includes developing a conceptual model for
integration, assessing the consistency of the evidence, applying the method
chosen for integration and developing the weight of evidence conclusion
(see Sections 2.4 and 4.4).
Line of evidence a set of evidence of similar type (see Section 2.1).
Meta-analysis a statistical analysis that combines the results of multiple scientiﬁc studies
(see Section 3.1.5).
OHAT An approach to systematic review and evidence integration for literature-
based environmental health science assessments, developed by the NTP
Ofﬁce of Health Assessment and Translation (OHAT) (see Rooney et al.
2014).
Piece of evidence A broad term used to refer to distinct elements of evidence that may be
combined to form a line of evidence, e.g. a single study, expert judgement
or experience, a model, or even a single observation (see Section 2.1).
Probability Deﬁned depending on philosophical perspective: (1) the frequency with
which samples arise within a speciﬁed range or for a speciﬁed category; (2)
quantiﬁcation of uncertainty as degree of belief regarding the likelihood of a
particular range or category (EFSA, 2016a–c). The latter perspective is
implied when probability is used in a weight of evidence assessment to
express relative support for possible answers (see Sections 2.3 and 2.6).
Problem formulation In the present guidance, problem formulation refers to the process of
clarifying the questions posed by the Terms of Reference, deciding whether
and how to subdivide them, and deciding whether they require weight of
evidence assessment (Section 2.2).
Qualitative assessment An assessment performed or expressed using words, categories or labels
(see Section 4.1 in EFSA, 2016a).
Quantiﬁcation A category of weight of evidence assessment methods deﬁned by Linkov
et al. (2009) as comprising formal decision analysis and statistical methods
(see Section 3.1). Would also include probabilistic reasoning.
Quantitative assessment An assessment performed or expressed using a numerical scale (see
Section 4.1 in EFSA, 2016a–c).
Rating A category of weight of evidence assessment methods for weighing and/or
integration of evidence based on qualitative logic models, ranks, scores and
empirical models (see Section 3.1).
Reﬁnement one or more changes to an initial assessment, made with the aim of
reducing uncertainty in the answer to a question. Sometimes done as part
of a ‘tiered approach’ to risk or beneﬁt assessment.
Relative support An expression of the extent to which evidence supports one possible
answer to a weight of evidence question, relative to other possible answers.
Can be expressed qualitatively or quantitatively (see Section 2.3).
Quantitative expression can be in terms of probability (see Section 2.6).
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Relevance The contribution a piece or line of evidence would make to answer a
speciﬁed question, if the information comprising the line of evidence was
fully reliable. In other words, how close is the quantity, characteristic or
event that the evidence represents to the quantity, characteristic or event
that is required in the assessment. This includes biological relevance (EFSA
Scientiﬁc Committee, 2017) as well as relevance based on other
considerations, e.g. temporal, spatial, chemical, etc. (see Section 2.5).
Reliability Deﬁned in this guidance as the extent to which the information comprising
a piece or line of evidence is correct, i.e. how closely it represents the
quantity, characteristic or event that it refers to. This includes both accuracy
(degree of systematic error or bias) and precision (degree of random error)
(see Section 2.5).
Sensitivity analysis A study of how the variation in the outputs of a model can be attributed to,
qualitatively or quantitatively, different sources of uncertainty or variability.
Implemented by observing how model output changes when model inputs
are changed in a structured way (EFSA, 2016a–c). See Section 4.6.
Standalone line of
evidence
A line of evidence which offers an answer to a question or subquestion
without needing to be combined with other lines of evidence (see
Section 2.1).
Standardised
assessment procedures
Assessments where the approach to integrating evidence is fully speciﬁed in
a standardised assessment procedure. They generally include standardised
elements that are assumed to provide adequate cover for uncertainty
(EFSA, 2016a–c). See also Section 4.
Uncertainty analysis A collective term for the processes used to identify, characterise, explain and
account for sources of uncertainty (EFSA, 2016a–c). See Sections 2.6 and 4.5.
Uncertainty A general term referring to all types of limitations in available knowledge
that affect the range and probability of possible answers to an assessment
question (EFSA, 2016a–c). See Section 2.6.
Variability Heterogeneity of values over time, space or different members of a
population, including stochastic variability and controllable variability (EFSA,
2016a–c). See Section 2.7.
Weighing the evidence The second of three basic steps of weight of evidence assessment, as
proposed in this guidance. Includes deciding what considerations are relevant
for weighing the evidence, deciding on the methods to be used, and applying
those methods to weigh the evidence (see Sections 2.4 and 4.3).
Weighing In this guidance, weighing refers to the process of assessing the
contribution of evidence to answering a weight of evidence question. The
basic considerations to be weighed are identiﬁed in this guidance as
reliability, relevance and consistency of the evidence (see Section 2.5).
Weight of evidence
assessment
A process in which evidence is integrated to determine the relative support
for possible answers to a scientiﬁc question (see Section 2.1).
Weight of evidence
conclusion
the outcome of a weight of evidence assessment, expressed in terms of
relative support for possible answers to the weight of evidence question
(see Section 2.3).
Weight of evidence
question
A question addressed by a weight of evidence assessment. This may be the
overall scientiﬁc question for an assessment, or a subquestion that
contributes to answering the overall question (see Section 2.2). Weight of
evidence questions may be framed in terms of hypotheses (which are often
qualitative) or estimates (quantitative).
Weight of evidence The extent to which evidence supports one or more possible answers to a
scientiﬁc question. Hence ‘weight of evidence methods’ and ‘weight of
evidence approach’ refer to ways of assessing relative support for possible
answers (see Section 2.3)
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AICR American Institute for Cancer Research
AMU Assessment Methodological unit
ECHA European Chemicals Agency
FAO Food and Agriculture Organization of the United Nations
GRADE Grading of Recommendations, Assessment, Development and Evaluation
IARC International Agency for Research on Cancer
IPCS International Programme on Chemical Safety
OECD Organisation for Economic Co-operation and Development
OHAT Ofﬁce of Health Assessment and Translation
PROMETHEUS promoting methods for evidence use in scientiﬁc assessments
SC Scientiﬁc Committee
SCCS Scientiﬁc Committee on Health and Environmental Risks
SCENIHR Scientiﬁc Committee on Emerging and Newly Identiﬁed Health Risks
SCHER Scientiﬁc Committee on Consumer Safety
SR systematic review
US EPA US Environmental Protection Agency
WCRF World Cancer Research Fund
WG Working Group
WHO World Health Organization
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Annex A – Illustration of the proposed approach to assess the Weight of
evidence: problem formulation, hierarchy of questions and mapping lines
of evidence for chemical risk assessment
Annex A provides examples of the application and reporting of the weight of evidence approaches
used in assessing chemical risks to human health and the environment in the context of EFSA’s
mandate. In the introductory part, general principles of conducting chemical risk assessments are
presented, and a decision tree provided to demonstrate data availability and how it drives the applied
approaches. This is followed by examples demonstrating different situations with regard to data
availability in human health risk assessment and an example of ecological risk assessment. In all cases,
speciﬁc questions are addressed.
A.1. Problem formulation
Problem formulation refers to framing of the scientiﬁc question(s) that are generally posed by a
decision maker or a stakeholder. It is important to ensure that the question(s) fully encompass the
issue(s) that need to be addressed, and are clear and agreed prior to the start of the assessment
(EFSA, 2015c). The WHO (2009) has regarded problem formulation as an iterative process involving
risk assessors and risk managers that determines the need for and the extent of a risk assessment.
According to the US EPA (2007), problem formulation is ‘a systematic planning step to identify the
major factors to be considered in a particular assessment in relation to preliminary hypotheses with
regards to hazard assessment (i.e. likelihood and severity of adverse effects which might occur or have
occurred) and exposure assessment (i.e. likelihood and signiﬁcance of exposure)’.
In a food safety context, a typical problem formulation may include a description of the intended
application (e.g. a food additive) and the commodities involved; issues expected to be affected (e.g.
human health), and potential consequences; consumer perception of the hazards or risks; and
distribution of possible risks among different segments of the population. The desired outcomes of
problem formulation are in the form of clear questions that need answering, identiﬁcation of the
resources and the timeframe that would be needed for the assessment. In relation to EFSA’s work,
problem formulation is often deﬁned in the Terms of Reference (ToR) provided by risk managers from
the European Commission or a Member State. Data requirements for premarket authorisation of a
substance are deﬁned in a number of regulation and guidance documents.
With regard to applying weight of evidence in such assessments, it is important to note that
problem formulation is a prerequisite and precedes the assessment, including the weighing and the
integration of the evidence. In the case of food chemicals, the problem may be too complex to be
addressed in a single question, and may need to be divided into more lower tier questions that can be
answered directly, and by combining the answers to these, the main question can be addressed. In
doing this, a hierarchy of questions is deﬁned. Relevant data/information can be collected, assessed,
weighed and integrated into separate lines of evidence that would answer each question at the bottom
of the hierarchy. Integration continues upward the question hierarchy until an overall integration can
be reached to respond to the main question.
A.2. Chemical risk assessment (human health)
The basic steps of a chemical risk assessment involve a structured way to address the hierarchy of
the question(s) for each step of the process, i.e. hazard assessment, exposure assessment and risk
characterisation. This gives the assessor a starting point to map the evidence needed for the
assessment in a particular context (e.g. regulated chemicals/products or contaminants for human
health or environmental risk assessment).
Human risk assessment of chemicals applied by EFSA to the food and feed safety area may include
the following generalised elements for hazard identiﬁcation and characterisation. For each of those
elements, different lines of evidence may be available and can be integrated depending on the
purpose of the assessment (e.g. a standard procedure, rapid risk assessment, chemical-speciﬁc
assessment), and availability of data, time and resources.
Hazard identiﬁcation
• Genotoxicity: in vitro studies such as bacterial Ames test and mammalian micronucleus assay;
in vivo studies; in silico models.
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• Toxicokinetics: in vivo studies on absorption, distribution, metabolism, excretion (ADME);
in vitro studies; in silico models.
• Toxicity/toxicodynamics: epidemiological and clinical studies; case reports; in vivo studies
(acute, subchronic, chronic toxicity, carcinogenicity, reproductive/developmental toxicity);
in vitro studies; in silico models.
Hazard characterisation (dose–response relationship to derive health based guidance values
(HBGV) or reference values (RVs) for margin of exposure (MOE).
• Toxicokinetics: in vivo and/ or in vitro studies on absorption, distribution, metabolism, excretion
(ADME), in silico models (toxicokinetic and/ or physiologically based models).
• Acute toxicity: in vivo studies, in vitro studies, case reports.
• Subchronic/chronic/carcinogenicity: epidemiological and clinical studies; in vivo studies
including pathological investigations, clinical chemistry; in vitro studies; in vivo and/or in vitro
OMICs studies (transcriptomics, proteomics, metabolomics, exposomics); in silico models; read-
across extrapolations; default values (e.g. threshold of toxicological concern (TTC)).
• Other studies (as necessary): e.g. studies on reproductive/developmental toxicity, neurotoxicity,
immunotoxicity.
Exposure assessment
• Occurrence: concentration of the chemical in food (total diet study, food monitoring, food
composition tables, etc.) or other media using results of analytical methods (high-performance
liquid chromatography (HPLC), gas chromatography (GC), mass spectrometry (MS), etc.),
default values (e.g. maximum residue levels (MRLs), maximum limits, etc.), in silico models.
• Food Consumption: (consumption surveys, food consumption and composition databases, e.g.
EFSA food consumption and composition databases, budget method, volume of production,
default value), in silico models.
Risk characterisation
• Compounds with threshold effects: comparison of health-based guidance value (e.g.
acceptable daily intake (ADI), tolerable daily intake (TDI)) with exposure estimates, MOE
approach for chemicals with insufﬁcient data to establish a TDI.
• Compounds with non-threshold effects (e.g. genotoxic and carcinogenic compounds) MOE
approach.
The cases described below relate to human risk assessment of regulated products for premarket
authorisation, as well as re-evaluation of regulated compounds and contaminants.
A.2.1. Human health risk assessment of regulated products for premarket
authorisation
For regulated substances (e.g. food and feed additives, ﬂavourings, food contact materials,
pesticides), minimum data requirements are provided in the respective European Commission
regulations and relevant guidance documents. The information is required to be submitted in a dossier
by any applicant who is seeking authorisation of a substance prior to placing it on the market (see, for
example, EFSA, 2012, 2014b). In these cases, problem formulation is often set by the European
Commission regulations and guideline documents, deﬁning the hierarchy of the questions for the
purpose of the assessment. Where there are data gaps in relation to hazard identiﬁcation/
characterisation, data/information derived from other methods, such as in silico modelling and read-
across, may be useful in ﬁlling the gaps. Similarly, in the absence of comprehensive data on the
occurrence in different food groups, exposure assessment may be based on point estimates.
A.2.2. Re-evaluation of human health risk assessment of existing regulated
products
For re-evaluation of regulated substances, available data may include an original dossier, and in
some circumstances in addition, historical assessments, and/or published studies in the scientiﬁc
literature or additional studies provided by applicants that can be used to address each question at
different steps of the risk assessment process. The availability of more detailed information would
provide more options for applying quantitative probabilistic methodologies.
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A.2.3. Human health risk assessment of contaminants
Some contaminants may result from food and feed processing, e.g. acrylamide, PAHs or from
natural sources such as toxins of plant, fungal or marine organism origin. Contaminants may also
include regulated chemicals that may have been removed from the market, e.g. brominated ﬂame
retardants, or other contaminants, e.g., metals, persistent organic pollutants. Although, in the case of
chemicals, the hierarchy of the question(s) still follows the structured steps of risk assessment, the
nature of the data available may vary enormously. This depends on whether an assessment had been
performed previously, or if the contaminant is new and emerging with limited safety data.
Consequently, methods to combine evidence may range from basic description of the evidence in data-
poor situations to full probabilistic assessment in data-based situations.
A.2.4. A tiered approach to map the level of knowledge and evidence available
for human health risk assessment of chemicals
Under the scenarios described above, a tiered approach has been illustrated in Figure A.1 with the
aim to map the level of knowledge and the type of evidence/data necessary to address the questions
for hazard characterisation of chemicals in human health risk assessment. The tiered approach has
been adapted from the WHO, the US EPA and EFSA (US EPA, 2007; Meek et al. 2011; EFSA, 2013).
The reader should consider each step of the risk assessment independently since the level of
knowledge can be any combination of data-poor and data-based situation for the exposure and/or
hazard identiﬁcation/ characterisation and consequently risk characterisation.
A.2.4.1. Weighing evidence for human risk assessment of chemicals
Once, in the problem formulation, the questions for data-poor and data-rich situations have been
deﬁned, and available data sources and data gaps have been identiﬁed, a hierarchy of questions can
be developed in relation to assembling, weighing and integrating the available evidence.
A.2.4.2. Hazard identiﬁcation and characterisation
The ﬁrst step involves searching for and selecting the evidence that is relevant for answering
the question(s) at hand and deciding if and how to group it/them into lines of evidence as needed. The
second step involves detailed evaluation and weighing of the assembled evidence. In the third step, the
evidence is integrated to arrive at conclusions. Each weight of evidence assessment is associated with
speciﬁc uncertainties that contribute to the overall uncertainty assessment (see Section 2.6 below).
Figure A.1 provides a decision tree which summarises each step of the weight of evidence analysis
for hazard identiﬁcation and hazard characterisation of chemicals in food in data rich and data poor
situations. These examples of weight of evidence assessment for hazard characterisation of a chemical
in these two data situations are given since these represent both ends of the spectrum EFSA Panels
may encounter, when dealing with human health risk assessment of chemicals. In the context of
authorisation of regulated compounds, data needs are determined by the relevant guidance and may
not cover all endpoints listed, e.g. derivation of a reference point (point of departure) and a health-
based guidance value. In some cases, data gaps for speciﬁc endpoints may be encountered. In such
cases, empirical data can be combined with estimates generated from in silico tools.
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Toxicological data
Hazard Assessment of a chemical in a food
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•Toxicokinetics – ADME
•Acute Toxicity
•Subchronic/Chronic Toxicity, Carcinogenicity
•Reproductive/Developmental Toxicity
•Other studies
•Clinical data
•Epidemiological data
Assemble evidence
Weigh Evidence
Integrate evidence
Clinical evidence
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TTC, In silico QSAR model, Read-across
1.   Identify relevant hazard evidence 
2.   Select relevant hazard evidence to include in WoE assessment
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Figure A.1: Generic decision tree for hazard identiﬁcation and hazard characterisation of chemicals in food in data rich and data poor situations
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A.2.4.3. Hazard identiﬁcation of an emerging contaminant for human health
The example presented below describes the use of weight of evidence in emerging contaminants.
They can be anthropogenic contaminants, e.g. brominated contaminants or result from food and feed
processing, e.g. newly identiﬁed Maillard reaction products or even from natural sources such as toxins
of plant, fungal or marine organism origin.
Preferably use multiple tools for the assessment, for instance, multiple QSAR models. Different in
silico tools will have different levels of transparency, and may be more or less relevant for the target
compound. Preference should therefore be given to the model(s) that also provide an assessment of
their applicability domain(s). A general strategy for weighing the evidence from different tools should
consider the following criteria:
1) Does the chemical possess a (structural/functional) feature that indicates potential for toxicity
(e.g. the presence of a structural alert)?
2) Are there other factors that may negate this feature (e.g. an exception rule to the structural
alert, or other inﬂuencing factors such as the lack of systemic absorption)?
3) Are there similar compounds with the same feature as the target compound (again considering
any counteracting factors)?
a) Do the similar compounds have the expected toxicity, as suggested by the presence of the
alert?
b) If there are no similar compounds with the relevant toxicity feature, are there other
structurally or functionally similar compounds that have been tested?
4) Do the results of the QSAR models support the focussed studies listed above?
Note that a compound may still be toxic even if it is not associated with any known alert or not
toxic even if it contains a structural alert for toxicity.
In straight forward cases, there is generally an agreement between the presence of a toxicity alert,
read-across from similar compounds and predicted toxicity by QSAR model(s). In more complex
situations, however, some alerts may conﬂict with the evidence from different methods, e.g. similar
compounds used in a read-across may have conﬂicting values, or the output from different QSAR models
may show disagreement. The use of more sophisticated in silico tools (such as the OECD toolbox, VEGA,
etc.) may help the expert in identifying any toxicity alerts in the target compound, and/or the presence
of the alerts in other similar compounds, as well as providing a measure of the uncertainty associated
with each alert and result of read-across/QSAR modelling.
Table A.1: Optional tabular format for summarising weight of evidence assessment for an emerging
contaminant
Question: Hazard identiﬁcation of an emerging contaminant
Assemble
the
evidence
Select evidence No toxicity data available: use read-across from already-tested similar
compounds, in silico tools (QSAR) to predict toxicity
Lines of Evidence Identify lines of evidence for potential effect(s) from the presence of a
structural alert or QSAR models, read-across from similar compounds
Weigh the
evidence
Methods Evaluate the reliability, relevance and consistency of the QSAR models. This
can include weighing model results on a statistical basis (e.g. likelihood of a
compound with a structural alert to express (a) toxic property(ies))
Results Toxicity value for each line of evidence, with associated assessment of
reliability (e.g. through the applicability domain of the models used)
Integrate
the
evidence
Methods If the estimates from the different models converge, the level of uncertainty
regarding the toxic property(ies) can be evaluated (e.g. through the
applicability domain of the models used). If the estimates do not converge,
further modelling for the toxic property(ies) could be undertaken to evaluate
whether the results can be improved
Results Integrated the toxicity value and uncertainty factor to derive a health based
guidance value for the emerging contaminant: Summary Table
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A.2.4.4. Example of the use of non-testing methods within a weight of evidence
framework
The example presented below describes the use of weight of evidence when information is derived
from non-testing methods (NTM), such as in silico models and read-across. Two in silico platforms –
VEGA (www.vega-qsar.eu) and T.E.S.T. (www.epa.gov/nrmrl/std/qsar/qsar.html#TEST) – have been
used to estimate mutagenicity (as assessed through the bacterial reverse mutation test) of the target
compound. A read-across software, ToxRead (www.toxread.eu), has also been used to provide
additional support for the results where necessary.
As shown in Table A.2, all models predicted the substance as non-mutagenic, except the CAESAR
model within the VEGA platform. Indeed, the target compound does not have a structural rule for
mutagenicity. On the contrary, seven rules associated with the lack of effect have been reported by
SARpy within the VEGA platform. Most of the similar compounds in this case are also not-mutagenic,
and the majority of the QSAR models used also indicate non-mutagenicity. Thus, the three main
elements in the evaluation using non-testing methods (structural rules, read-across from similar
compounds and QSAR models) agree on the lack of mutagenic effect. These results are based on
experimental values for structurally similar compounds and on the results of the QSAR models, using
both rule- and statistically based models. Since no rule has been identiﬁed for mutagenicity, reasoning
for the mechanism is not applicable. The read-across tool (ToxRead) conﬁrms that the substance
should not be regarded mutagenic.
However, two indications for mutagenicity need further explaining. First, the CAESAR model
indicates mutagenicity, and there is a structurally similar compound (CAS 1250-95-9) that is reported
mutagenic by both VEGA and T.E.S.T. The applicability domain of the CAESAR model for this
compound is nevertheless weak, and the software indicates a particular warning highlighting this
aspect. This, coupled with the fact that similar compounds in the training sets are also non-mutagenic,
suggests that the model prediction for mutagenicity of the target compound is not correct. The VEGA
software clearly indicates that the very likely reason of the mutagenic effect of the structurally similar
compound is the presence of an epoxide moiety. However, this moiety is not present in the target
Figure A.2: shows chemical structure of the compound used in in silico assessment of toxicity
Table A.2: Summary of the results obtained by different non-testing methods
Software Model/method Results Applicability Domain Index
T.E.S.T. Consensus method
Hierarchical method
FDA method
Nearest neighbour method
Mutagenicity negative
Mutagenicity negative
Mutagenicity negative
Mutagenicity negative
Internally checked
VEGA Consensus model
CAESAR(a)
SARpy3
ISS3
KNN3
Non-mutagenic
Mutagenic
Non-mutagenic
Non-mutagenic
Non-mutagenic
0.719
0.853
0.786
0.819
ToxRead Read-across Non-mutagenic Not available
(a): These are the names of models as found in VEGA (www.vega-qsar.eu).
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compound, and therefore, this conﬂicting prediction can be disregarded. This example shows proper
use of the criterion about relevance of the line of evidence. In this case, mutagenicity of similar
substances with moieties that are not present in the target compound makes them non-relevant to the
target compound.
The reliability of the other lines of evidence is addressed in this case through the use of the
measurement of the applicability domain, as in Table A.2. In this way, the user can integrate the
different lines of evidence, keeping into account their relevance, reliability, and consistency.
The read-across software (ToxRead) provides further support to this conclusion. Most of the closely
related substances (Figure A.3) show a lack of mutagenicity, whereas one similar compound which is
mutagenic (indicated in red circle) is in fact the same as discussed above.
The overall conclusion that can be drawn from this exercise is that the substance in question is very
likely not mutagenic (90% of probability).
This example illustrates how different tools can be used to derive toxicity estimates for a given
compound in the absence of experimental data. Some of these tools may be rule-based (e.g. VEGA
ISS), statistically based (e.g. T.E.S.T) and tools which offer both these approaches, and thus go
beyond simple prediction and provide elements for explicit reasoning. For example, some programmes
(e.g. VEGA) provide necessary details that facilitate the reasoning, and thus increase the acceptance of
the results. The read-across tool, ToxRead, provides a weight of evidence program that can integrate
results from QSAR and read-across. As shown in the example above, any contradictory results from
the different methods need to be explored further before considering or disregarding them. Therefore,
such tools must not be used as a ‘black box’, and the ﬁnal assessment must be carried out by an
expert.
Figure A.3: ToxRead chart (www.toxread.eu). The numbers refer to CAS identiﬁers. Straight arrows
link the target chemical to rules, while curved arrows link to chemicals
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A.2.4.5. Example of the use of human epidemiological data within a weight of
evidence framework: The cadmium example
The CONTAM Panel performed a human risk assessment for cadmium in food in 2009 (Amzal et al.,
2009; EFSA, 2009) and its assessment is an example of the use of a weight of evidence (WoE)
approach using human epidemiological data to derive a reference point based on benchmark dose limit
(BMDL). Cadmium (Cd) is a heavy metal found as an environmental contaminant, both through natural
occurrence and from industrial and agricultural sources. Foodstuffs are the main source of cadmium
exposure for the non-smoking general population. Cadmium absorption after dietary exposure in
humans is relatively low (3–5%), but cadmium is efﬁciently retained in the kidney and liver in the
human body, with a very long biological half-life ranging from 10 to 30 years.
The CONTAM Panel considered human studies relating to urinary cadmium and urinary biomarkers
of toxicity for kidney toxicity (N-acetyl-f3-glucosaminidase, beta–microglobulinuria (B2-M), alpha-1-
microglobulinuria, urinary retinol-binding protein, proteinuria) and bone effects (bone mineral density,
alkaline phosphatase activity, serum calcium, parathyroid hormone) using a systematic review of the
literature. Based on the literature availability at the time, expert judgement and previous international
risk assessments (JECFA, ATSDR), the CONTAM Panel concluded that B2-M was the most reliable,
relevant and consistent urine biomarker for Cd-induced renal tubular toxicity with 35 studies reporting
continuous variables as preferable for benchmark dose modelling.
A Bayesian meta-analysis and hierarchical modelling was performed to build an overall dose-effect
relationship accounting for interstudy heterogeneity and for inter-individual variability of dose and
Table A.3: Optional tabular format for summarising weight of evidence assessment of an emerging
contaminant
Question Hazard identiﬁcation of an emerging contaminant
Assemble
the evidence
Select evidence Nine QSAR models from two in silico platforms and a program for read–
across were used to estimate mutagenicity potential (as assessed through
bacterial reverse mutation test) of the target compound
Lines of evidence Except two, all estimates indicated the compound to be non-mutagenic.
The exception was the QSAR model CAESAR within VEGA platform that
predicted the compound as mutagenic, and the read-across programme
ToxRead that showed one out of ﬁve similar compounds to be mutagenic
Weigh the
evidence
Methods VEGA provides a quantitative measurement of reliability and values higher
than 0.8 ADI are considered more reliable. T.E.S.T. applies a ﬁlter to
eliminate not reliable predictions. The results obtained from these platforms
in this case are therefore reliable. ToxRead indicates the alerts associated
with the effect and similar compounds. In case of chemicals with the
toxicity value conﬂicting with the rule, the user should check if there are
rules present only in the similar compound and not in the target, explaining
the conﬂicting toxicity value. This is useful to evaluate the relevance of the
lines of evidence, disregarding those that are not relevant
Results T.E.S.T. results consistently indicated non-mutagenicity. The VEGA models
called SARpy and KNN showed higher indices for reliability, also predicted
non-mutagenicity. The CAESAR and ISS models within the VEGA models
showed relatively lower reliability. ToxRead results show that most of the
compounds similar to the target compound were not-mutagenic. The only
structural rule for mutagenicity found in one similar compound is not
present in the target compound, and therefore is not relevant
Integrate
the evidence
Methods The in silico estimates have been integrated while considering the reliability
and relevance of the individual values, together with the consistency of all
the predicted values, to make an informed expert judgement about the
probability that the target compound is not-mutagenic
Results The large majority of the in silico values are in concordance for non-
mutagenicity of the target compound. One conﬂicting estimate is less
reliable whereas the other is not relevant to the target compound.
Considering all the evidence from this in silico assessment, it was concluded
by informed expert judgement that the target compound is most likely
(about 90% probability) to be non-mutagenic
ADI: Applicability Domain Index.
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effect. Subsequently, a BMDL was evaluated using a hybrid approach for various cut-offs. As a lower
and more protective cut-off level, the Panel proposed a biological cut-off for B2-M of 300 lg/g
creatinine from expert judgement and clinical evidence that exceeding such a threshold is associated
with an accelerated age-related decline renal function together with increased mortality (Amzal et al.,
2009). The CONTAM Panel selected an overall group-based BMDL5 of 4 lg cadmium/g creatinine. The
use of 300 g B2-M/g creatinine as critical effect of cadmium exposure to base the risk assessment
leads to a possible overestimation of the risk, but is protective of the most sensitive groups of the
population. A summary of the WoE assessment for deriving a BMDL for cadmium is presented in
Table A.4.
Table A.4: Summary of the weight of evidence assessment for the derivation of a human reference
point (benchmark dose limit) for cadmium in food
Question
Deriving a reference point (benchmark dose limit) for cadmium in
humans (hazard characterisation)
Assemble the
evidence
Select evidence Systematic review of human studies relating urinary cadmium and excretion
of biomarkers of toxicity
Select relevant papers: biomarkers of kidney and bone effects with
continuous outcome to include in WoE assessment
Lines of evidence Urinary cadmium and renal effects
LOE 1: N-acetyl-f3-glucosaminidase (NAG)
LOE 2: beta-microglobulinuria (B2-M)
LOE 3: alpha-1-microglobulinuria
LOE 4:urinary retinol-binding protein (RBP)
LOE 5: proteinuria
Urinary cadmium and bone effects
LOE 1: bone mineral density (bone MD)
LOE 2: Alkaline phosphatase activity (bALP)
LOE 3: serum calcium
LOE 4: parathyroid hormone (PTH)
Weigh the
evidence
Methods 1. Assess reliability, relevance and consistency by expert judgement
2. Select WoE Method: Quantitative method as meta-analysis using
Bayesian hierarchical mixed effect model to build dose-response
relationship between urinary cadmium and urinary B2-M
3. Conclusion for WoE Assessment: Dose-effect relationship accounting for
inter-study heterogeneity and for inter-individual variability of urinary
cadmium and excretion of B2-M selected for the modelling
Results Overall 35 studies B2-M studies (LOE 1) were selected as most relevant,
consistent and reliable including previous meta-analysis and assessments
from ATSDR, WHO Urinary cadmium and B2-M selected for meta-analysis
based on biological relevance of the biomarker for cadmium toxicity,
reliability and consistency of the human database
Integrate the
evidence
Methods Meta-analysis of the dose-effect relationship between urinary cadmium and
B2-M accounting for interstudy heterogeneity and for interindividual
variability of dose and effect using Bayesian hierarchical mixed effect model
Expert judgement was used to select biologically relevant cut off values for
urinary B2-M reﬂecting renal tubular damage (300 lg B2-M/g creatinine).
Exceeding such a cut off value has been associated with an accelerated
age-related decline of renal function together with increased mortality
Derive the reference point based on benchmark dose limit (BMDL5)
modelling for urinary B2-M using hybrid approach and urinary cadmium
Results The meta-analysis and dose–response modelling based on B2-M as a
marker of tubular effect, identiﬁed an overall group based BMDL5 for a 5%
increase of the prevalence of elevated B2-M of 4 lg cadmium/g creatinine.
This is selected as a reference point
WoE: weight of evidence; LOE: line of evidence.
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A.2.4.6. Example of the use of weight of evidence framework in derivation of an
acceptable daily intake (ADI) for a regulated chemical
EFSA may derive an acceptable daily intake (ADI) for regulated products that are likely to be present
in food or feed. The ADI is an estimate of the amount of a chemical that can be consumed on a daily
basis over a lifetime without appreciable health risk. Within the context of EFSA risk assessments, ADIs
are derived for food and feed additives, and pesticide residues. An applicant wishing to market a
regulated product is required to demonstrate its safety by providing data from relevant toxicity studies,
from which an ADI can be derived. For example, the EFSA Panel on Food Additives and Nutrient Sources
added to Food (ANS) uses a tiered approach with increasing data requirement in higher tiers reﬂecting
greater potential risk (EFSA, 2012, 2014d). The data set needs to address toxicokinetics, genotoxicity,
subchronic toxicity, chronic toxicity, carcinogenicity, reproductive toxicity and developmental toxicity.
These studies may be performed in several species such as rat, mouse, dog, rabbit and each type of
study per species constitutes a line of evidence (LOE) (Table A.5).
For each line of evidence, effect data from the different species may be compared qualitatively to
identify the no-observed-adverse-effect-level (NOAEL) for the most sensitive species and endpoint
taking into account biological relevance, reliability and consistency of the data. Alternatively,
benchmark dose modelling could be performed on the results from each study using model averaging
according to the guidance of EFSA scientiﬁc Committee (EFSA Scientiﬁc Committee, 2017).
Quantitative comparison of the results of the BMDL for each study and LOE can then be carried out to
determine a BMDL for the most sensitive species and endpoint taking into account biological relevance,
reliability and consistency of the data.
An ADI is ﬁnally derived by dividing the NOAEL or BMDL by an appropriate uncertainty factor to
account for differences in TK and TD between experimental animals and human (10-fold), and
variability among humans (10-fold). An additional uncertainty factor may in some cases be applied to
account for severity of the effect or deﬁciency in the data.
Table A.5: Summary of the weight of evidence assessment for the derivation of an acceptable daily
intake (ADI) for a regulated non-genotoxic chemical
Question
Derivation of an acceptable daily intake (ADI) for a regulated
non-genotoxic chemical
Assemble the
evidence
Select evidence In the context of a regulated compound, toxicity studies that may be
used to derive an ADI are illustrated below (this list is not exhaustive).
These studies may be performed in several species namely rat, mouse,
dog, rabbit, and each type of study per species constitute a line of
evidence
Lines of evidence Examples include
LOE 1: subchronic toxicity study 28 days
LOE 2: subchronic toxicity study 90 days
LOE 3: developmental toxicity study
LOE 4: one generation reproductive toxicity study
LOE 5: chronic toxicity studies (e.g. 1 year toxicity study)
LOE 6: Two-year carcinogenicity study
Weigh the
evidence
Methods A number of options may be available depending on the speciﬁc
assessment.
Generic examples are illustrated below:
1) Qualitative comparison of each LOE per species to derive a
reference point such as a BMDL or a no-observed-adverse-
effect-level (NOAEL) for the most sensitive species and
endpoint taking into account biological relevance, reliability
and consistency of the data
2) Benchmark dose modelling using model averaging according
to the guidance of EFSA scientiﬁc Committee (EFSA Scientiﬁc
Committee, 2017). Quantitative comparison of the results of
the BMDL for each study and LOE to determine a BMDL for
the most sensitive species and endpoint taking into account
biological relevance, reliability and consistency of the data
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A.3. Chemical risk assessment (Environment)
While environmental risk assessment of chemicals follows basically the same conceptual framework
like that for human health, it is not identical. For hazard identiﬁcation, all available studies are
assessed, and the most sensitive are selected. Available data are integrated to derive a guidance value
such as a regulatory acceptable concentration. In the risk characterisation step, actual environmental
exposure levels are compared with this guidance value.
Figure A.4 provides a decision tree for environmental hazard characterisation of a chemical in data-
based and data-poor situations.
Question
Derivation of an acceptable daily intake (ADI) for a regulated
non-genotoxic chemical
3) Expert judgement to assess whether an extra UF is
needed for the severity of the effect or uncertainty in
the DB for the NOAEL or the BMDL
Results Possible outcomes include:
• Reference point (BMDL or NOAEL) value for the regulated
compound for the most sensitive species and endpoint BMDL or
NOAEL selected as a reference point
• The quality of the studies in terms of relevance, reliability and
consistency do not allow the derivation of a reference point
• No effects were observed at the highest dose tested and there
is no need to derive a numerical reference point
• Decision as to whether an extra UF should be applied and how
large it should be
Integrate the
evidence
Methods Quantitative methods: combination of reference point and default
uncertainty factors
Results A number of options may be available depending on the speciﬁc
assessment. Four options are illustrated below:
1) Derivation of the ADI applying the default uncertainty factor
of 100 to the NOAEL, taking into account species differences
(10-fold) and human variability (10-fold)
2) Derivation of the ADI applying the default uncertainty factor
of 100 to the BMDL taking into account species differences
(10-fold) and human variability (10-fold)
3) Derivation of the ADI applying the default uncertainty factor
of 100 and an extra uncertainty factor for the severity of the
effect (e.g. carcinogenicity) or uncertainty in the database to
the NOAEL or BMDL
4) Derivation of the ADI is not possible since regulatory
requirements are not met and additional toxicity studies are
required
5) Derivation of a numerical ADI is not needed since regulatory
requirements are met and no adverse effects were observed
at the highest dose tested
LoE: line of evidence.
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Ecotoxicological data
Hazard Assessment of a chemical in environmental 
compartment
Data rich scenario
e.g. (re)evaluation of a regulated chemical or contaminant
Data poor scenario
e.g. an emerging contaminant 
•Toxicokinetics – ADME
•Acute Toxicity
•Subchronic/Chronic Toxicity
•Reproductive/Developmental Toxicity
•Mesocosm studies
•Field studies
Assemble evidence
Weigh Evidence
Integrate evidence
In silico, QSAR model, Read-across
In silico, QSAR model, Read-across
In silico, QSAR model, Read-across
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In silico QSAR model, Read-across
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Results
Read-across
Read-across
1.   Identify relevant ecotoxicological evidence 
2.   Select relevant hazard evidence to include in   
WoE assessment
3.   Group Hazard evidence into lines of evidence 
1. Assess consistency of hazard evidence
2. Apply method for integrating hazard evidence 
3. Summarise all results in concise tabular or graphical
4. Apply WoE method and summarise results in useful form for integration
1. Assess reliability, relevance and consistency
2. Select WoE Method (e.g. listing of evidence, best professional judgement; 
causal criteria; rating (logic, scoring,  indexing), quantitative methods (e.g
meta-analysis))
3. Define how to express conclusion of WoE assessment
1. Report results
2. Analyse uncertainty and data gaps
3. Conclusde on  WoE and uncertainty for Hazard characterisation of chemical
I
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Figure A.4: Decision tree for environmental risk assessment of a chemical in data rich and data poor situations
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A.3.1. Ecotoxicological hazard characterisation of a regulated substance
Ecotoxicity studies from the dossier: in vivo studies from the dossier (lethality, developmental,
reproductive, acute, subchronic and chronic toxicity). Select most sensitive biologically relevant
endpoints from a study or all studies when available for a speciﬁc group of animals (see note 1). Where
more studies are available for the ecotoxicological characterisation than the basic dossier requirements,
select most sensitive biologically relevant endpoints by comparing all studies. Use default assessment
factor (see note 2) when only dealing with dossier studies, or assess whether there is a need to divert
from the default assessment factor on the basis of the available information for assessing the uncertainty
and/or variability. Integrate ecotoxicity values and assessment values to derive environmental based
guidance value (or regulatory acceptable concentration) for a regulated compound.
The Table below shows an example assessment according to the Guidance on tiered risk
assessment for plant protection products for aquatic organisms in edge-of-ﬁeld surface waters (EFSA,
2013)
References
EFSA, 2009. Scientiﬁc Opinion of the Panel on Contaminants in the Food Chain on a request from the European
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0800317
Table A.6: Summary of the weight of evidence assessment for plant protection products for aquatic
organisms in edge-of-ﬁeld surface waters
Question
Assessing a regulatory acceptable concentration (RAC) for ﬁsh
for compound Ideﬁx
Assemble the
evidence
Select evidence Take the ecotoxicological information from the dossier
Lines of evidence Acute toxicity values:
LOE 1: 5-day LC50 study with Oncorhynchus mykiss of 12 mg/L
LOE 2: 5-day LC50 study with Lepomis macrochirus of 47 mg/L
Chronic toxicity studies:
LOE 1: 35-day NOEC study (ELS) with Oncorhynchus mykiss of 0.8 mg/L
LOE 2: 35-day NOEC study (ELS) with Lepomis macrochirus of 0.5 mg/L
Standard/default assessment factors:
LOE 1: for acute situation assessment factor is 100
LOE 2: for chronic situation assessment factor is 10
Weigh the
evidence
Methods Take lowest value according to the method described in the guidance
document and apply appropriate assessment factor. If this results in
concern being raised, consider by expert judgement whether to use an
alternative value, e.g. the geometric mean (EFSA 2005)
Results For the acute situation, the lowest toxicity value is 12 mg/L
For the chronic situation the lowest toxicity value will 0.5 mg/L
Integrate the
evidence
Methods Quantitative combination of a point estimate with a default value
Results For the acute situation, the RAC is 12/100 = 0.12 mg/L
For the chronic situation, the RAC is 0.5/10 = 0.05 mg/L
Note 1. Here available studies are part of a dossier. In case of a new compound/product, the dossier will contain only the
ecotoxicological studies required by legislation. This could be one or (in a few cases) two studies. Standard ecotoxicological
studies are performed on behalf of, or by, the applicant, which implies that there are also standard endpoints which are in most
cases considered as biologically relevant. There are also standard species tested, e.g. Daphnia magna as the standard species for
crustaceans or the rainbow trout as the standard species for ﬁsh. The weight of evidence in those cases has been applied
before, choice of representative species or biological relevant endpoints (Commission Regulation (EU) No 283/2013, Commission
Regulation (EU) No 284/2013). The uncertainties around the hazard c.q. risk assessment are assumed to be covered by the
assessment factor that is used for decision making on whether or not to allow the compound on the market or for going to
higher tier risk assessment steps.
Note 2. It is assumed that the assessment factors are only to be used for the uncertainty inherent to the ecotoxicity values and
that the uncertainty around the exposure value is included in the assessment of the exposure value, for instance by using the
90th percentile of the exposure distribution.
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Annex B – Examples of weight of evidence deﬁnitions, criteria and outputs
from the scientiﬁc literature
This Annex contains examples referred to in Section 2 of the Guidance, on three topics:
• Examples of deﬁnitions and descriptions of weight of evidence (Table B.1).
• Examples of deﬁnitions and descriptions of ‘Line of evidence’ from the published literature
(Table B.2).
• Examples of criteria for weighing evidence from the published literature, mapped onto the
three general concepts of reliability, relevance and consistency (Table B.3).
All three tables contain examples from a selection of publications on weight of evidence
assessment. They do not comprise a systematic or comprehensive review.
Table B.3 aims to show how various criteria used in the literature relate to the three basic concepts
introduced in Section 2.5 of this Guidance: reliability, relevance and consistency. Many publications on
weight of evidence approaches specify criteria to be considered when weighing evidence. Some of
these criteria are very general, applying to virtually any context. Others are expressed in ways that are
more speciﬁc to particular problem areas, e.g. the essentiality of key events (Collier et al., 2016). As
may be expected, in some cases different publications use different words to express what appear to
be similar criteria.
Criteria referring to the quality of studies or data, risk of bias, imprecision and sensitivity are all
factors affecting the reliability of a piece of evidence in itself. They are all aspects of the way a study
(for example) was conducted or reported, which affect the reliability of the resulting evidence as a
correct representation of what actually occurred in the study.
Relevance concerns the relation between evidence and a purpose for which it is being used, i.e. the
question it is being used to address. Confounding is a factor affecting relevance, because it concerns
the possibility that an observed effect may have been caused by agents or factors other than the one
of interest for the question in hand. The same applies to other criteria relating to attribution of an
effect, e.g. speciﬁcity, temporality, essentiality, experimentation and randomised trials. Criteria such as
spatial and temporal representativeness concern the relevance of the conditions in which evidence was
generated to the conditions for the question being assessed: for example, if the assessment question
refers to the EU as a whole, old data from one EU Member state is less relevant than new data from
an EU-wide study (other things being equal).
Some criteria refer to the magnitude or statistical signiﬁcance of measurements, or of dose-response
and other forms of association or correlation (including spatial and temporal correlation). These criteria
can contain elements of both reliability and relevance. For example, when an observed effect is large in
magnitude and/or shows a consistent trend or association (referred to as ‘strength’ of evidence by Suter
and Cormier, 2011), then it is more likely to be real (reliability of the ﬁnding) and more likely to be caused
by the agent of interest or more likely to be large enough to be important (relevance to the question).
Therefore, in this guidance, ‘strength’ is considered to contribute to reliability and relevance, and not a
separate criterion distinct from reliability and relevance (as in Suter, 2016).
Some other types of criteria can also inﬂuence both reliability and relevance. For example, the use
of standard methods, the clarity and completeness of reporting and the extent of evaluation and peer
review all inﬂuence judgements about both the reliability and relevance of evidence.
Many publications include criteria relating to the consistency of evidence. Consistency intrinsically
includes the notions of quantity and diversity, because consistency has more weight when seen in a
larger body of evidence, and/or when the evidence is of diverse types. Many publications include
explicit criteria for consistency, quantity or diversity of evidence, or obviously related criteria such as
coherence, reproducibility and replicability. Some of the other criteria in Table B.3 refer particular types
of consistency: for example, concordance and analogy both refer to whether there is consistency
between the evidence being considered and established knowledge or theory, and hence with the
evidence on which the knowledge or theory is based. ‘Biological plausibility’ usually refers to
consistency between data and biological theory or mechanism. Similarly, ‘experimental veriﬁcation’
refers to one piece of evidence being supported by another.
Criteria listed in the right hand column of Table B.3 are of a different nature. ‘Adequacy’ is
mentioned by several publications but refers to standards against which reliability, relevance and
consistency should be judged, rather than being a separate criterion. ‘Validity’ also implies a
comparison with some standard. In the context of weight of evidence, validity could refer to meeting
standards for reliability (e.g. required levels of precision and accuracy), but it can also refer to meeting
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standards for relevance (e.g. appropriate test subjects and route of exposure) or even consistency.
‘Plausibility’ as a general term (distinct from ‘biological plausibility’, see above) is not really a separate
criterion, rather it is a function of the three basic criteria identiﬁed in the guidance: relevance,
reliability and consistency all contribute to plausibility. It can be regarded as synonymous with the
‘relative support’ for a given estimate or hypothesis, e.g. regarding a stressor or mechanism. SCENIHR
(2012) propose that assessors should ‘identify uncertainties in the judgement used’ in the weight of
evidence process: this refers to the need to consider uncertainties affecting the assessment of
reliability, relevance and consistency, rather than being a separate criterion.
Table B.1: Examples of deﬁnitions and descriptions of weight of evidence
Publication Deﬁnitions or descriptions given for weight of evidence
Agerstrand and Beronius (2016) ‘In general terms, weight of evidence and systematic review are processes of
summarising, synthesising and interpreting a body of evidence to draw
conclusions . . . these processes differ from the traditional method for risk
assessment by promoting the use and integration of information from all the
available evidence instead of focusing on a single study’
ANSES (2016) Deﬁnes weight of evidence as ‘the structured synthesis of lines of evidence,
possibly of varying quality, to determine the extent of support for hypotheses’
Beronius et al. (2014) States that ‘The meaning of weight of evidence intended here is the collective
summary and evaluation of all existing evidence after a certain “weight” has
been attributed to individual studies, e.g. by evaluating reliability and relevance’
Collier et al. (2016) Describes weight of evidence as ‘a term used in multiple disciplines to
generally mean a family of approaches to assess multiple lines of evidence in
support of (or against) a particular hypothesis, although (it) tends to be used
inconsistently and vaguely across disciplines’
ECHA (2015a) [Guidance on the
Application of the CLP Criteria]
‘A weight of evidence determination means that all available information
bearing on the determination of hazard is considered together’
ECHA (2015b) [Guidance on the
Biocidal Products Regulation]
‘A weight of evidence assessment involves the consideration of all data that is
available and may be relevant to reproductive toxicity’
ECHA (2010) ‘One deﬁnition for weight of evidence is: “the process of considering the
strengths and weaknesses of various pieces of information in reaching and
supporting a conclusion concerning a property of the substance”’
EFSA (2013) [PPR Aquatic Ecol
RA guidance doc]
States that the ‘process of combining available lines of evidence to form an
integrated conclusion or risk characterisation is frequently referred to as weight-
of-evidence assessment. This term reﬂects the principle that the contribution of
each line of evidence should be considered in proportion to its weight’
EPA (2003) Describes weight of evidence as an ‘approach (which) considers all relevant
information in an integrative assessment that takes into account the kinds of
evidence available, the quality and quantity of the evidence, the strengths and
limitations associated with each type of evidence and explains how the various
types of evidence ﬁt together’
Good (1979, 1985) Deﬁnes weight of evidence as the logarithm of the ratio of the likelihood of a
given hypothesis to the likelihood of an alternative hypothesis. This expression
corresponds to the Bayes factor
Hope and Clarkson (2014) Refers to Good for quantitative deﬁnition
Describes weight of evidence as ‘basically the process of considering the
strengths and weaknesses of various pieces of information in order to inform a
decision being made among competing alternatives’
Hull and Swanson (2006) Describes weight of evidence as ‘approaches (that) integrate various types of
data (e.g., from chemistry, bioassay, and ﬁeld studies) to make an overall
conclusion of risk’
Linkov et al. (2009) Deﬁnes weight of evidence as ‘a framework for synthesising individual lines of
evidence, using methods that are either qualitative (examining distinguishing
attributes) or quantitative (measuring aspects in terms of magnitude) to
develop conclusions regarding questions concerned with the degree of
impairment or risk’
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Publication Deﬁnitions or descriptions given for weight of evidence
NRC (2009) States that ‘The phrase weight of evidence is used by EPA and other scientiﬁc
bodies to describe the strength of the scientiﬁc inferences that can be drawn
from a given body of evidence’.
Lorenz et al. (2013) Deﬁnes ‘weight of evidence framework’ as ‘approaches that have been
developed for taking the process from scoping an assessment and initial
identiﬁcation of relevant studies through the drawing of appropriate
conclusions’
Schleier et al. (2015) Describes weight of evidence as ‘approaches in which multiple lines of
evidence can be considered when estimating risk’
Suter and Cormier (2011) ‘In sum, weighing evidence is a synthetic process that combines the
information content of multiple weighted pieces of evidence. The information
may be dichotomous (supports or not), quantitative values (e.g., an exposure
or risk estimate), qualitative properties (e.g., large, medium or small), or a
model. The weights that are applied to the information may express various
properties that affect its credibility or importance and the weights themselves
may be qualitative or quantitative. The combining of evidence may be a simple
quantitative operation (e.g., weighted averages of concentration estimates)
but more often involves difﬁcult qualitative judgments’
Vermeire et al. (2013) Implicit deﬁnition: ‘The different and possibly contradictory information is
weighted and the respective uncertainties taken into account in a weight of
evidence approach’
Weed (2005) Identiﬁes three characteristic uses of the term weight of evidence:
metaphorical, methodological and theoretical. Does not propose a deﬁnition
but recommends that authors using weight of evidence should deﬁne the term
and describe their methods
WHO (2009) Deﬁnes weight of evidence as ‘a process in which all of the evidence
considered relevant for a risk assessment is evaluated and weighted’
SCENIHR (2012), Meek et al.
(2014)
Uses the term weight of evidence but do not include an explicit deﬁnition or
summary description
Rooney et al. (2014) (OHAT),
Morgan et al. (2016) (GRADE)
These publications do not use the term weight of evidence but rather use
related terms including ‘evidence synthesis’ and ‘evidence integration’
Table B.2: Examples of deﬁnitions and descriptions of ‘line of evidence’ from the published
literature
Agerstrand and Beronius
(2016)
Line of evidence used only when quoting EFSA (2013) Guidance on assessment of
pesticide risks to aquatic organisms
ANSES (2016) Deﬁnes line of evidence as ‘A set of relevant information of similar type grouped to
assess a hypothesis’
Bradford Hill (1965) Not used
Collier et al. (2016) Uses line of evidence frequently. Does not provide an explicit deﬁnition, but
Table A.1 appears to imply that the evidence relating to the molecular initiating
event, the adverse outcome, and to each key event is considered as one line of
evidence in each case
ECHA (2010) Line of evidence not mentioned as such. Refers to weighing pieces of evidence; also
refers to weight of evidence providing ‘the opportunity to make use of less reliable
information/studies when they are pooled together with other information’.
However, ‘pooling’ here may refer to the body of evidence as a whole rather than to
creating subsets of evidence
EFSA (2013) PPR
Panel Aquatic RA Guidance
States that ‘the contribution of the multiple assessment approaches (multiple lines
of evidence) in reducing overall uncertainty can . . . be evaluated by weight of
evidence in the ﬁnal risk characterisation’, implying that in this context an line of
evidence is an ‘assessment approach’
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US EPA (1998) Two page section on lines of evidence
‘The development of lines of evidence provides both a process and a framework for
reaching a conclusion regarding conﬁdence in the risk estimate’
‘Conﬁdence in the conclusions of a risk assessment may be increased by using
several lines of evidence to interpret and compare risk estimates. These lines of
evidence may be derived from different sources or by different techniques relevant
to adverse effects on the assessment endpoints, such as quotient estimates,
modeling results, or ﬁeld observational studies’
‘The phrase lines of evidence is used to de-emphasise the balancing of opposing
factors based on assignment of quantitative values to reach a conclusion about a
‘weight’ in favor of a more inclusive approach, which evaluates all available
information, even evidence that may be qualitative in nature. It is important that
risk assessors provide a thorough representation of all lines of evidence developed
in the risk assessment rather than simply reduce their interpretation and description
of the ecological effects that may result from exposure to stressors to a system of
numeric calculations and results’
EPA (2003) Refers to use of line of evidence by US EPA (1998) guideline for ecological RA, but
does not use the term further
Hope and Clarkson (2014) Line of evidence used extensively but no explicit deﬁnition
Hull and Swanson (2006) Does not deﬁne line of evidence but refers to toxicity tests and population or
community survey measures as examples of lines of evidence
Linkov et al. (2009) Uses line of evidence several times. Does not provide own deﬁnition but when
reviewing the US EPA (1998) guidance for ecological RA says that ‘a weight of
evidence evaluation treats each assessment and measurement endpoint as an
individual line of evidence’
Meek et al. (2014) Line of evidence not used
Morgan et al. (2016)
(GRADE)
Line of evidence not used
National Research Council
(U.S.) Committee on
Improving Risk Analysis
Approaches Used by the
U.S. EPA (2009)
Not used
Lorenz et al. (2013) Line of evidence used several times but no deﬁnition found
Rhomberg et al. (2015) Line of evidence used in one place without deﬁnition. Also, uses ‘lines of argument
(or hypotheses)’
Rooney et al. (2014)
(OHAT)
Line of evidence not used. Text refers to studies and body of evidence, and to
‘streams of evidence’ which are described as referring to the speciﬁc categories of
human data, animal data, and ‘other relevant data including mechanistic or in vitro
studies’
SCENIHR (2012) Uses ‘lines of evidence’ throughout. Does not provide an explicit deﬁnition but page
9 gives lists of lines of evidence, e.g. for hazard assessment the list comprises
epidemiology studies, human volunteer studies, other human data, animal studies,
in vitro studies, in silico studies, mathematical modelling, and mechanistic/mode of
action studies; while for exposure assessment the list comprises exposure
measurements, mathematical modelling and toxicokinetics
Schleier et al. 2015 Do not deﬁne line of evidence but refer to ‘integrating multiple
lines of evidence from different study types’
Suter and Cormier (2011) Uses ‘Categories of evidence’ in similar manner to line of evidence. Does not provide
an explicit deﬁnition for Categories. Includes ‘lines of evidence’ in list of keywords
and uses it several times but does not explain how it relates to ‘Categories’. Also
uses ‘body of evidence’ which is deﬁned in their Section 3.3.1 as all of the weighted
categories of evidence for a hypothesis, but is also used in the ﬁrst part of their
Sections 3–10 studies of the same type, i.e. ‘body’ also can refer to multiple pieces
of evidence in a single category
Vermeire et al. (2013) Line of evidence not used
Weed (2005) Line of evidence used once, when quoting a US EPA document
WHO (2009) Line of evidence not in glossary or cumulative index
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Table B.3: Examples of criteria for weighing evidence from the published literature, mapped onto the three basic concepts of reliability, relevance and
consistency introduced in Section 2.5
Publication Reliability Relevance
Combination of reliability and
relevance
Consistency Other
Bradford Hill
(1965)
Temporality
Experimentation
Speciﬁcity
Strength of association
Biological gradient
Consistency of association
Biological plausibility
Coherence
Analogy
Collier et al.
(2016)
Uncertainty and variability
(treatment of)
Applicability and utility
Essentiality of key events
Soundness
Evaluation and peer review
(extent of)
Clarity and completeness (of
reporting)
Consistency
Biological concordance
Concordance of empirical
observations among key events
Analogy (to other chemicals)
ECHA (2010) Reliability Relevance Quantity (in particular if
contradictory info is present)
Adequacy for
classiﬁcation and RA
US EPA (1998) Adequacy and quality of data
Degree and type of
uncertainty associated with
the evidence
Relationship of the evidence
to the risk assessment
questions
EPA (2003) Uncertainty and variability
(treatment of)
Applicability and utility Soundness
Clarity and completeness (of
reporting)
Evaluation and peer review
(extent of)
Hope and
Clarkson (2014)
Study quality Site speciﬁcity
Spatial representativeness
Temporal representativeness
Speciﬁcity to stressor
Use of standard methods
Endpoint/attribute association
Exposure/response function
Sensitivity to stressor
Quantiﬁcation of response
Hull and
Swanson (2006)
Speciﬁcity of cause Magnitude
Biological gradient/strength
Uncertainty
Spatial correlation
Temporal correlation
Consistency of association
Experimental veriﬁcation
Plausibility:
mechanism
Plausibility: stressor
Essentiality of key events
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Publication Reliability Relevance
Combination of reliability and
relevance
Consistency Other
Meek et al.
(2014)
Consistency
Biological concordance
Concordance of empirical
observations among key events
Analogy (to other chemicals)
Morgan et al.
(2016) (GRADE)
Risk of bias
Imprecision
Publication bias
Indirectness
Confounding
Study design (randomised or
observational)
Effect size
Dose response
Inconsistency
Lorenz et al.
(2013)
Study design
Bias/chance
Reliability
Statistical methods
Internal consistency
Confounders
Temporality
Relevance
Strengths & weaknesses
Dose response
Predictivity
Strength of association
Replicability (if observed)
Biological plausibility
Adequacy
Rooney et al.
(2014) (OHAT)
Risk of bias (15 subquestions)
Imprecision
Publication bias
Rare outcomes
Indirectness
Residual confounding
Effect magnitude
Dose response
Consistency ‘Other’ (unspeciﬁed)
SCENIHR (2012) Quality
Reliability
Relevance/potential
importance
The characterisation of the
stressor
The relevance of the set of
data for a particular
endpoint
Utility (combining quality and
relevance)
Soundness and appropriateness of
the methodology used
The extent to which the full
details of methodology are
provided
The reproducibility of ﬁndings
between experiments
Consistency
Validity
Uncertainties in the
judgement used
Suter and
Cormier (2011)
Performance
Statistical analysis
Potential for bias
Relevance
Inherent weights of study
types (e.g. randomised vs
observational, ﬁeld vs lab)
Study design
Reporting
Strength
Number of pieces
Coherence
Diversity
Case-speciﬁc criteria
Vermeire et al.
(2013)
Sensitivity
Reliability
Relevance
Speciﬁcity
Predictivity Adequacy
Validity
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Annex C – Examples of the application of approaches for assessing weight
of evidence in different areas of work of EFSA
C.1. NDA Panel example
Summary of the weight of evidence assessment for the Scientiﬁc Opinion on the
substantiation of a health claim related to vitamin D and risk of falling pursuant to Article
14 of Regulation (EC) No 1924/2006
Background information
Information about how the evidence is weighted in scientiﬁc assessments for health claims other
than those related to well-established functions of essential nutrients can be extracted from existing
guidance documents to applicants (EFSA NDA Panel, 2016a,b). For nutrition claims, and for health
claims related to well-established functions of essential nutrients, the scientiﬁc evidence is generally
not weighed.
The main question to be addressed is always the same. Is a health claim related to a speciﬁc food/
constituent4 and to a speciﬁc health effect scientiﬁcally substantiated? This main question can be
broken down into three subquestions, namely:
1) Is the food/constituent sufﬁciently characterised?
2) Is the claimed effect a beneﬁcial physiological effect (relevant to human health) for the
target population and can it be measured in vivo in humans?)
3) Is there a cause and effect relationship between the consumption of the food/constituent
and the claimed effect (for the target population, under the proposed conditions of use)?
A negative answer to any of the above-mentioned questions could stop the scientiﬁc evaluation by
the NDA Panel leading to a negative conclusion (i.e. the proposed health claim is not scientiﬁcally
substantiated). If a cause and effect relationship is considered to be established, an additional
question should be addressed in order to establish the conditions of use for the claim:
4) What is the (lowest) effective dose and the pattern of consumption required to obtain the
claimed effect?
Human studies are needed for the scientiﬁc substantiation of health claims. While animal and
in vitro studies can be used to assess the biological plausibility of the effect, they alone cannot
substantiate a health claim, and thus guidance documents contain little information on how to appraise
these studies individually or weigh them within the totality of the evidence.
Each relationship between a food/constituent and a claimed effect is assessed by the NDA
Panel separately on a case by case basis for speciﬁc claim applications. Pertinent human studies are an
absolute requirement for the scientiﬁc substantiation of health claims, and pertinent human efﬁcacy
studies are at the top of the hierarchy that informs decisions on substantiation. However, there is no
pre-established rule as to how many or which types of studies are needed for substantiation. The
reproducibility of the effect of the food/constituent, as indicated by the consistency of the ﬁndings
(within and across studies), and the biological plausibility of the effect are also considered.
A hierarchy of evidence for substantiation is given as follows (in decreasing order of importance):
a) Human intervention studies
b) Human observational studies: prospective cohort studies, nested-case control or case-cohort
studies, cross-sectional studies, ecological studies
c) Summary studies (systematic reviews, meta-analysis).
There are a series of questions to be considered for each type of human study to decide on
whether to include them or not among the totality of evidence which will be pertinent to the claim (i.e.
on whether or not they will be considered in the weighing of the evidence). For human intervention
studies, aspects related to their relevance, such as how the intervention relates to the food/constituent
that is the subject of the health claim, how the study population relates to the target population for
the claim and how the outcome variables relate to the claimed effect, are considered ﬁrst. Relevant
(pertinent) human intervention studies are then assessed in relation to their reliability (risk of bias) by
4 Food/constituent means a food category, a food or a food constituent (e.g. a nutrient or other substance, or a ﬁxed
combination of nutrients/other substances)
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carefully considering aspects such as randomisation, appropriateness of the control group, the use of a
placebo, blinding, whether the duration of the intervention is sufﬁcient to observe the expected
changes, and whether the statistical analysis of data is appropriate. For observational studies,
appropriate control for confounders is an important aspect. No scoring system is in place, however, to
rate the overall risk of bias of individual studies.
If a summary publication (including systematic reviews and meta-analysis) is provided for the
scientiﬁc substantiation of a claim, the Panel reviews the primary data to ensure that all the individual
studies included are relevant (pertinent) to the claim. Meta-analysis can provide information about the
reproducibility and consistency of the effect across studies and study groups, about the dose–response
relationship, and about the minimum effective dose of the food/constituent which is required to obtain
the claimed effect (i.e. to establish conditions of use). The NDA Panel, however, has not relied so far
on the results of meta-analyses to make a scientiﬁc judgement on whether a cause and effect
relationship between the consumption of the food/constituent and the claimed effect has been
established (EFSA NDA Panel, 2016a).
Health claim related to vitamin D and risk of falling
This is a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006 and falls under the
scope of disease risk reduction.
In order to assess the scientiﬁc substantiation of a health claim related to vitamin D and risk of
falling, the Panel considered the following in relation to the ﬁrst two questions (EFSA NDA Panel,
2011):
1) The food/constituent proposed by the applicant, vitamin D (D2 and D3), was sufﬁciently
characterised.
2) The claimed effect was ‘reduces the risk of falling. Falling is a risk factor for fractures’, and
the proposed target population for the claim was men and women 60 years of age
and older. Risk of falling is an established risk factor for fractures in the target population,
and can be assessed in human studies as the number of falls per person per observation
time (incidence), the total number of falls and/or the number of subjects falling at least
once).
To complete the assessment of the scientiﬁc substantiation of the claim, two main questions remain
to be assessed:
3) Is there a cause and effect relationship between the consumption of vitamin D and the risk
of falling in men and women 60 years of age and older?If so,
4) What is the (lowest (4a)) dose of vitamin D and the pattern of consumption required to
reduce the risk of falling in men and women 60 years and older (4b)?5
Tables C.1 and C.2 below summarise how the NDA Panel weighed and integrated the evidence in
order to answer questions 3 and 4, respectively. Different sections of the scientiﬁc opinion (EFSA NDA
Panel, 2011) are cross-referenced.
Table C.1: Summary of how the NDA Panel weighed and integrated the evidence in order to
answer question 3.
Question
Is there a cause and effect relationship between the
consumption of vitamin D and the risk of falling in men and
women 60 years of age and older?
Assemble the
evidence
Select evidence The opinion is based on the evidence provided by the applicant. Details
on the literature search and inclusion/exclusion criteria applied by the
applicant are given in the ﬁrst paragraph of Section 3 of the opinion.
The Panel selected the studies/meta-analysis relevant (pertinent) to the
claim by considering whether they were designed to address the
speciﬁc question (see second paragraph of Section 3 of the opinion and
ﬁrst paragraph under ‘randomized controlled trials’)
5 It should be noted that question 4 is conditional to question 3 (i.e. it is only addressed if the answer to question 3 is positive).
Guidance on the weight of evidence
www.efsa.europa.eu/efsajournal 56 EFSA Journal 2017;15(8):4971
Question
Is there a cause and effect relationship between the
consumption of vitamin D and the risk of falling in men and
women 60 years of age and older?
Lines of evidence LOE 1. Six RCTs investigating the effects of vitamin D supplementation
on the risk of falling in the target population
LOE 2. Five observational studies investigating the association between
vitamin D supplementation and/or vitamin D status (as a surrogate
marker of total vitamin D intake) and risk of falling in the target
population
LOE 3. Data (from RCTs and observational studies) and background
expert knowledge on the mechanisms by which vitamin D could reduce
the risk of falling (biological plausibility of the effect)
Weigh the
evidence
Methods LOE 1. Narrative based on expert discussion
LOE 2. Narrative based on expert discussion
LOE 3. Narrative based on expert discussion
Results LOE 1. Five RCTs showed an effect of vitamin D on the risk of falling in
the target population at daily doses of 800–1,000 I.U. (20–25 lg); one
four-arm study using vitamin D doses of 200–800 I.U. (5–20 lg) did
not show an effect, but it might have been underpowered for that
outcome (see Section 3 of the opinion, penultimate paragraph under
‘randomized controlled trials’
LOE 2. Results from the observational studies provided were
inconsistent; residual confounding could not be excluded (see Section 3
of the opinion under ‘observational studies’)
LOE 3. Given the well-established role of vitamin D on muscle function,
it is biologically plausible (but still to be established) that vitamin D
supplementation could improve muscle strength, physical performance
and body balance in the target population (see Section 3 of the
opinion, ﬁrst paragraph under ‘mechanisms of action’)
Integrate the
evidence
Methods LOE 2 was dismissed, rather than integrated with Line 1. Integration
of LOEs 1 and 3 was done by expert discussion as explained in the last
two paragraphs but one of Section 3 in the opinion
Results The Panel concludes that a cause and effect relationship has been
established between the intake of vitamin D and a reduction in the risk
of falling (Section 3 of the opinion, last paragraph) in the target
population for the claim, which is men and women 60 years of age and
older (Section 5 of the opinion)
Table C.2: Summary of how the NDA Panel weighed and integrated the evidence in order to
answer question 4
Questions
What is the (lowest (4a)) dose of vitamin D and the pattern of
consumption required to reduce the risk of falling in men and
women 60 years and older (4b)?
Assemble the
evidence
Select evidence The applicant provided a meta-analysis of eight RCTs which aimed to
investigate the efﬁcacy of supplemental vitamin D with or without
calcium in preventing falls among older individuals. Two of the RCTs,
however, were not considered pertinent to the claim, and thus
secondary analyses were conducted to assess the dose-response
relationship and the risk of publication bias (see Section 3 of the
opinion under ‘meta-analysis of randomized controlled trials’)
Lines of evidence LOE 1. Six RCTs pertinent to the claim
LOE 2. Funnel plot for risk of publication bias analysis
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C.2. PPR Panel
Summary of the weight of evidence assessment for the substantiation of pesticidal
active substances to be included in Cumulative Assessment Groups (CAGs)
Background
In 2013, the PPR Panel developed a methodology to identify pesticidal active substances to be
included in Cumulative Assessment Groups (CAGs). It was assumed that compounds belonging to the
same CAG can be treated in cumulative risk assessment as if they were simple dilution of one other
and will follow the dilution principles of dose addition (EFSA, 2013).
The methodology was intended to address cumulative effects in relation to maximum residue limits
(MRLs) setting. Four levels of grouping were proposed, each indicating a reﬁnement step in the
methodology.
CAG level 1: common toxicological target organ;
CAG level 2: common speciﬁc phenomenological effect;
CAG level 3: common mode of action (if available);
CAG level 4: common mechanism of action (if available).
Since information on mode and mechanism of action is frequently not available, reﬁnement to CAG
level 3 and 4 was inconclusive for most of the CAGs and the induction of the same phenomenological
Questions
What is the (lowest (4a)) dose of vitamin D and the pattern of
consumption required to reduce the risk of falling in men and
women 60 years and older (4b)?
Weigh the
evidence
Methods LOE 1. Meta-analysis of the six RCT pertinent to the claim
LOE 2. Assessment of the risk of publication bias
Results LOE 1. No conclusions can be drawn from the meta-analysis with
respect to the effect of vitamin D supplementation on the risk of falling
at doses of 200–600 I.U./day (5–15 lg/day). No dose–response can be
identiﬁed. The meta-analysis consistently shows, however, a signiﬁcant
effect of vitamin D supplementation on the risk of falling (RR = 0.83;
95% CI: 0.75–0.92) at doses of 800–1,000 I.U./day (20–25 g/day)
LOE 2. No signiﬁcant publication bias was identiﬁed. The risk of bias
was quantiﬁed
Integrate the
evidence
Methods The Copas model was used to adjust the effect of vitamin D
supplementation at doses of 800–1,000 I.U./day (20–25 g/day) on the
risk of falling for possible publication bias (RR = 0.85; 95% CI: 0.75–0.96)
Results The available data do not provide information about the lowest
effective dose of vitamin D needed to obtain the claimed effect
(subquestion 4a). In order to obtain the claimed effect, 800 I.U.
(20 lg) of vitamin D from all sources should be consumed daily
(subquestion 4b) (see Section 3 of the opinion under ‘meta-analysis
of randomized controlled trials’, last paragraph; see also Section 5 of
the opinion on conditions and restrictions of use)
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effect was deemed sufﬁcient for accepting similar action and therefore justiﬁes dose addition. The
methodology for grouping substances in CAG level 2 involves the identiﬁcation and characterisation of
the speciﬁc effect. Identiﬁcation of the speciﬁc effect was based on the following criteria: exclusion
of local effect, exclusion of non-adverse effects, exclusion of effects not relevant to humans, evaluation
of unambiguous nature of the effect, identiﬁcation of non-speciﬁc effect. The characterisation of the
speciﬁc effect is described by supporting indicators, e.g. histological, biochemical or clinical indicators.
The methodology developed by the PPR Panel was substantiated by expert knowledge (EFSA, 2013).
Following establishment of the criteria, a data collection including authorised and non-authorised
substances was performed by collecting data from the dossiers submitted for the authorisation
procedure and the active substances matching with the established criteria were included in the CAGs.
These CAGs were deﬁned at level 2, and often contain large numbers of substances.
Assuming that all the substances in a level 2 CAG combine by dose addition may lead to a large
overestimation of risk if some or many of them do not, in fact, share the same mechanism of action.
Therefore it is relevant for the risk assessors and the risk managers to consider the level of conﬁdence
or certainty that a given substance belongs to a CAG at levels 3 or 4 and consequently contributes to
the cumulative risk assessment (CRA) by dose addition.
Example
The following example is proposing a weight of evidence approach using a pre-established CAG
level 1 nervous system and CAG level 2 autonomic response (acute). The methodology also includes
the selection of a Reference Compound which was selected on the consistency and robustness of the
database (e.g. dose-related effect, consistently observed across the studies, known pesticidal mode of
action, known toxic mode of action). Four lines of evidence were identiﬁed for assessing whether each
substance should qualify for combining with the reference compound by dose addition, and criteria
were deﬁned for weighing each line of evidence on scales expressed as 0/+ or 0/+/++ (see below for
details). The lines of evidence were then integrated by expert judgement, expressing the conclusion
for each substance in terms of the probability that it qualiﬁed for dose addition, expressed on a scale
of 0–100%. This can then be used in cumulative risk assessment to take account of the conﬁdence
that each substance should be included or excluded in dose addition, using probability theory, whereas
there would be no such theoretical basis if the conclusion was expressed qualitatively (e.g. as the
number of + scores).
This approach requires that the question addressed by the probability for each substance should be
well-deﬁned. It was considered that dose addition could be assumed for a given substance (Y) if it
causes a signiﬁcant effect on the autonomic nervous system (CAG level 2) and has a key event (e.g.
biochemical effect) that is (a) in common with substance X (the reference compound) and (b) has a
causal relation to the adverse outcome (AO). The approach to the weight of evidence assessment for
this question is summarised in Table C.3, and results for a selection of substances are shown in
Table C.4. As a ﬁnal step, the elicited probability was assigned to one of the categories on a probability
scale suggested in the draft EFSA Guidance on Uncertainty (see Table C.5).
Table C.3: Summary of proposed approach
Question
Does substance Y cause a signiﬁcant effect on autonomic (CAG level 2)
and have a key event (e.g. biochemical effect) that is (a) in common with
substance X (the reference compound) and (b) has a causal relation to
the AO and therefore justiﬁes dose addition? (This question is assessed
separately for each substance Y in the Level 2 CAG, except for the
reference substance X)
Assemble the
evidence
Select evidence Data were collected from the authorisation dossiers and draft
assessment reports (DAR) using criteria deﬁned in EFSA, 2013. Data
collection is available on EFSA, 2012 and 2015
Lines of evidence LOE 1: speciﬁcity of the effect/dose relationship
LOE 2: clinical observation
LOE 3: biochemical observation
LOE 4: MoA
Note that lines 1 and 2 relate to CAG level 2, whereas LOEs 3 and 4
relate to CAG level 3 or 4
Guidance on the weight of evidence
www.efsa.europa.eu/efsajournal 59 EFSA Journal 2017;15(8):4971
Question
Does substance Y cause a signiﬁcant effect on autonomic (CAG level 2)
and have a key event (e.g. biochemical effect) that is (a) in common with
substance X (the reference compound) and (b) has a causal relation to
the AO and therefore justiﬁes dose addition? (This question is assessed
separately for each substance Y in the Level 2 CAG, except for the
reference substance X)
Weigh the
evidence
Methods LOE 1: 0 No dose relationship, + Effect observed at the high dose only,
++ Effect showing a dose relationship
LOE 2: 0 No, + Yes
LOE 3: 0 Not observed, + biochemical read-out observed at the high
dose only, ++ biochemical read-out showing a dose relationship
LOE 4: 0 Not established, + presumed, ++ known
Results See Table 2
Integrate the
evidence
Methods Expert knowledge elicitation (EKE) was the selected methodology to
integrate the evidence and express the conclusion as a probability. The
methodology followed the principles of the EFSA (2014) EKE guidance,
modiﬁed for application to the case in hand (a binary question) and
streamlined to be practical for application to multiple substances
Results The conclusion was expressed as the probability that substance Y
causes an autonomic effect and has a shared KE with the reference
substance. This can be used in a cumulative risk model to take account
of the degree of conﬁdence that Y and X should be combined by dose
addition
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Table C.4: Example of preliminary results. CAG: Autonomic division, Acute
Active
substance
Indicator of
speciﬁc
effect
NO(A)EL LO(A)EL
Mode/mechanism
of action
Study
Lines of evidence
mg/kg bw mg/kg bw
Is the effect
speciﬁc and
therefore dose
related? 0 = not
speciﬁc + = only
observed at high
dose ++ = dose
related
Is the effect
deﬁned at
clinical level?
0 = No, + = Yes
Is the effect
deﬁned at
biochemical
level? 0 = No,
+ = Yes,
++ = Yes, dose
related
Is the effect
supported by a
mechanism of
action? 0 = No
+ = presume
++ = Yes
Expert
Knowledge
Elicitation
Probability
scale
Oxamyl
(reference
compound)
Salivation,
urination
0.1 0.75 Known, inhibition of
AChE
Acute neurotoxicity
rat
++ + ++ ++ 100% Extremely
Likely
Acetamiprid Urination 10 30 Known, nicotinic
acetylcholine receptor
(nAChR) agonist
Acute neurotoxicity
rat
++ + 0 ++ 50% As likely as not
beta-Cyﬂuthrin Salivation 2 10 (only
observed at
high dose)
Presumed, type II
(a-cyano) pyrethroid
Acute neurotoxicity
rat
+ + 0 + 33% Unlikely
Dicofol Lacrimation
salivation
25 250 Unknown Acute neurotoxicity
rat
++ + 0 0 40% As likely as not
Tebuconazole Salivation 250 500 (only
observed at
high dose)
Unknown Acute neurotoxicity
rat
+ + 0 0 30% Unlikely
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C.3. FEEDAP Panel example
Subject: Scientiﬁc Opinion on safety and efﬁcacy of Cygro® 10G (maduramicin
ammonium a) for chickens for fattening. EFSA Journal 2011;9(1):1952
Background
Additives for use in feed are substances of very different nature, ranging from trace elements (such
as copper or zinc, usually in the form of salts) to viable microorganisms (silage agents or probiotics).
They are categorised according to their functions and properties (technological, sensory, nutritional,
zootechnical, coccidiostats and histomonostats). Moreover, some applications for feed additives do not
have a speciﬁc holder and the additive is evaluated in a generic way (i.e. not linked to a concrete
product). For these reasons, the assessment of feed additives is complex and varies according to the
nature of the product.
The evaluation of feed additives involves its characterisation, its safety and its efﬁcacy. The safety
assessment needs to answer the following questions:
Question 1. Is the additive safe for the target animals (i.e. the animals for which the additive is
intended to)?
Question 2. Is the additive safe for the consumers (of the animals fed that additive)?
Question 3. Is the additive safe for the users (such as farmers and other operators handling the
product)?
Question 4. Is the additive safe for the environment?
As an example, here is discussed how the evidence was weighted and integrated to answer
Question 1 for one feed additive (Cygro® 10G, maduramicin ammonium a) under the category
coccidiostats and histomonostats.
Evaluation of Cygro® 10G (maduramicin ammonium a) for chickens for fattening
For the evaluation of the additive Cygro® 10G (a coccidiostat with maduramicin ammonium a as
active principle) for chickens for fattening, the FEEDAP Panel weighed and integrated the evidence as
summarised in the following Table.
Table C.5: Draft probability scale suggested by EFSA (2016a–c)
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C.4. GMO Panel Example
EFSA GMO Panel scientiﬁc opinion on the safety of the newly expressed PjD6D and
NcD15D proteins in soybean MON 87769
Background information
Genetically modiﬁed organisms (GMO) are ‘regulated products’ under EU legislation. In particular,
Regulation (EC) No 1829/2003 (European Commission, 2003) and Implementing Regulation (EU)
No 503/2013 (European Commission, 2013) require regulatory approval and a premarket safety
assessment of GM products before they can be introduced into the European market. The safety
assessment of foods and feeds derived from GMOs, relies on an internationally harmonised stepwise,
Table C.6: Summary of proposed approach
Question Is the additive safe for the target animals?
Assemble the
evidence
Select evidence The evidence was obtained:
• from the applicant in the technical dossier linked to the
application
• From previous opinions of the FEEDAP Panel
Lines of evidence 1) Tolerance studies with the additive in poultry (two studies)
2) Measurements of the minimum inhibitory concentration (MIC)
of maduramicin ammonium against microbial strains (two
studies)
3) Studies on the compatibility of maduramicin ammonium with
the antibiotic tiamulin (one study and one previous opinion
from the FEEDAP Panel)
Weigh the
evidence
Methods Assessment of the quality and validity of the studies and weighting of
the evidence was performed qualitatively by best professional
judgement. For this, the studies were ﬁrst assessed against the
requirements on the corresponding guidance documents, and then
checked for their methodological design and coherence of results
Results Main outcomes:
• One tolerance study is of limited value because of the difference
between the intended and measured concentration of
maduramicin ammonium in feed
• In the other tolerance study, zootechnical parameters are of
limited value because the low number of animals tested
Main outcome:
• Previous studies on interactions between ionophore
anticoccidials and tiamulin are well established The provided
study does not enable to establish the full compatibility between
both substances
Main outcome:
Integrate the
evidence
Methods Best professional judgement is the method used by the FEEDAP
Panel to integrate lines of evidence of different nature, in order to
achieve conclusions for complex questions in which different subjects
need to be answered
Results The different lines of evidence enabled to conclude that:
• The highest proposed dose for the additive seems close to the
intolerance level but it was not possible to derive a margin of
safety, due to the limitations of the tolerance studies
• It is unlikely that the additive will adversely affect the overall
gut microbiota
• In the absence of a clearly characterised compatibility, it is not
advisable to use the product with tiamulin
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comparative approach, in which the GMO is compared to a non-GM counterpart with a history of safe
use (Codex Alimentarius, 2009; EFSA GMO Panel, 2011). This usually entails a characterisation of the
GMO at various levels of molecular organisation, including the analysis of changes caused by the
genetic modiﬁcation at the level of newly inserted DNA and newly expressed proteins encoded by the
introduced DNA. This comparison also comprises an extensive analysis of the chemical composition
and agronomic/phenotypic characteristics of the GMO vs its non-GM counterpart, taking into account
the natural variability of all measured endpoints, which is estimated measuring the background range
of variation observed for known commercial varieties with a history of safe use. The differences
identiﬁed further guide the risk assessment and allow the identiﬁcation of those aspects of the GMO
needing further safety evaluation via speciﬁcally designed studies, taking into account the host
organism, the type of genetic modiﬁcation and the outcome of the comparative assessment. A number
of topics relevant for food and feed safety commonly assessed in all dossiers submitted for regulatory
pre-market safety assessment of GMOs, is as follows:
• occurrence of intended and possible unintended changes of the composition and other host
characteristics;
• potential toxicity of the compound(s) introduced or whose level(s) have been altered in the
host organisms by the genetic modiﬁcation;
• potential allergenicity of newly expressed protein(s) given that the vast majority of the
constituents responsible for allergenicity of foods are proteins;
• potential impact of the GM food or feed on human and animal nutrition (e.g. in case the
nutritional characteristics of the GMO have deliberately been modiﬁed, such as in the case of
GM soybean with changed oil composition).
Moreover, the environmental impact of the introduction of the GMO into the environment, through
cultivation of a GM crop by European farmers or through spillage of imported seed must be
considered. Items evaluated during the environmental risk assessment of a GM crop include, but are
not limited to, change in persistence and invasiveness of the GM crops, impact on the potential
horizontal gene transfer of introduced DNA to recipients (e.g. microorganisms), interaction with
non-target organisms and impact of the management practices applied to the GM crop.
From a general point of view, this wide variety of data straddling that serves as basis for the
assessment of the safety of a GMO calls for an application of the weight of evidence approach. Yet for
GMO safety assessment, ‘Weight of evidence’ is explicitly referred to only for the evaluation of its
potential allergenicity.
For allergenicity assessment of newly expressed proteins, the weight of evidence approach followed
takes into account all of the information obtained on the newly expressed protein, since no single
piece of information or experimental method yields sufﬁcient evidence to predict allergenicity. For this
assessment, all available information including tests of different nature will add to the weight of
evidence (EFSA, 2006; Codex Alimentarius, 2009; EFSA GMO Panel, 2011). The information relevant
for the assessment will include:
• information on the source of the transgene (i.e. the new genes introduced into the host
through genetic modiﬁcation), i.e. does the source have a history of allergies among patients
sensitive towards it?
• bioinformatics analysis searching for similarities between amino acid sequences of the newly
expressed protein and those of known allergens, based on sequence information in protein
sequence repositories;
• pepsin resistance test (in vitro degradation study under model conditions with the gastric
protease pepsin) as an indicator of the likelihood that the protein may withstands enzymatic
degradation (as some but not all allergenic proteins are known to sustain degradation to pepsin);
• on a case-by-case basis, speciﬁc human sera analysis with sera from patients allergic to the
source of the transgene and/or to allergenic proteins showing similarity. Finally, in vitro cell
based assays and/or in vivo tests using animal models (these tests are still in an experimental
stage of development for this purpose but under speciﬁc circumstances they could add to the
weight of evidence).
The ‘weight of evidence’ assessment is used to allow the risk assessor to conclude with a sufﬁcient
degree of certainty on the likelihood of the newly expressed protein not being allergenic, taking into
account the outcomes of various tests, none of which in its own right would be fully predictive of
allergenicity.
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As an example of the application of approaches for assessing weight of evidence in GMO, the
following question is addressed: are the newly expressed PjD6D and NcD15D proteins in soybean MON
87769 safe for human and animals?
An EFSA GMO Panel opinion on soybean MON 87769 has been published in 2014 (EFSA GMO Panel,
2014).
Question
Are the newly expressed PjD6D and NcD15D proteins in
soybean MON 87769 safe for humans and animals?
Assemble the
evidence
Select evidence The EFSA GMO Panel scientiﬁc opinion is based on the evidence
provided by the applicant in the initial application as well as additional
information provided by the applicant, scientiﬁc comments submitted by
the Member States and relevant scientiﬁc publications. Details on the
evidence considered for the safety assessment is provided in
Section 5.1.2 and 5.1.4 of scientiﬁc opinion on soybean MON 87769
Lines of evidence A summary of the evidence provided for the newly expressed PjD6D
and NcD15D proteins is as follows:
LOE 1. Available reports on the safety of the source of the transgenes,
i.e. the PjD6D and NcD15D genes originate from Primula juliae and
Neurospora crassa, respectively. Furthermore, information on the PjD6D
and NcD15D proteins which are desaturases naturally occurring in
plants
LOE 2. Bioinformatics analyses studies of the amino acid sequences of
the newly expressed PjD6D and NcD15D proteins searching for relevant
similarities with known toxins and allergens
LOE 3. The resistance to degradation by pepsin of the newly expressed
proteins studied in solutions at pH~1.2. In addition, heat denaturation
of the newly expressed proteins investigated under several conditions
of temperature
LOE 4. Acute toxicity testing employing single-dose oral toxicity studies
with the newly expressed PjD6D and NcD15D proteins
Weigh the
evidence
Methods LOE 1. Best professional judgement
LOE 2. Best professional judgement
LOE 3. Best professional judgement
LOE 4. Best professional judgement
Results LOE 1. The genes originate from sources that are not considered to be
common allergenic food. Some species of Primula are known to give
rise to contact dermatitis, but not reported in P. juliae and is primarily
due to benzoquinones and related compounds. N. crassa is used for
food preparation in some regions of the world. In addition, the PjD6D
and NcD15D proteins in soybean MON 87769 are desaturases sharing
partial identity with other desaturases naturally occurring in plants used
for food production
LOE 2. Bioinformatics analyses of the amino acid sequences of the
newly expressed proteins in soybean MON 87769 showed no relevant
similarities with known toxins or allergens
LOE 3. Protein degradation and denaturation studies did not raise
safety concerns. No intact protein was seen within 30 seconds of
incubation with pepsin at pH 1.2. Several shorter fragments were
observed after different incubation times. Many of these were most
likely co-puriﬁed proteins. Other fragments disappeared after 10
minutes of incubation. In addition, a signiﬁcant loss of immunoreactivity
was observed after 15 minutes at 95°C
LOE 4. No adverse effects of the PjD6D and NcD15D proteins were
observed at the doses tested when administered to CD-1 mice
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Question
Are the newly expressed PjD6D and NcD15D proteins in
soybean MON 87769 safe for humans and animals?
Integrate the
evidence
Methods LOE 4 was of little value for the risk assessment of the repeated
consumption of food and feed from GM plants by humans and animals.
Integration of LOEs 1, 2 and 3 was done by best professional
judgement as explained in the paragraph below
Results The PjD6D and NcD15D proteins are integral membrane fatty acid
desaturases and the scientiﬁc literature does not indicate that known
toxic proteins have such desaturase activity as a component of their
biological activity. Furthermore, these proteins or their sources are not
considered common allergenic food. Bioinformatics did not reveal amino
acid sequence homology of the PjD6D and NcD15D proteins with
known toxins or allergens. Humans and animals consume other
desaturases daily with no reported adverse effects. The PjD6D and
NcD15D intact proteins were degraded by pepsin in vitro
The EFSA GMO Panel concludes that there are no indications from the
information available to suppose that the speciﬁc desaturases PjD6D
and NcD15D in soybean MON 87769 would introduce safety concerns
for humans and animals
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C.5. ANS Panel Example
Regulation (EC) No 1331/2008 establishes a common authorisation procedure for food additives,
food enzymes and food ﬂavourings.
The common procedure lays down the arrangements for updating the lists of substances authorised
to be placed in the European Union market.
According to this procedure, EFSA is requested by the European Commission to provide scientiﬁc
opinions on the proposed updates of the existing positive lists. This applies to:
• adding new substances to the existing lists;
• adding, removing or changing conditions, speciﬁcations or restrictions associated with the
presence of a substance on the Community list.
The information provided in the opinion of EFSA should be sufﬁcient to ascertain whether the
proposed use of the substance is safe for consumers. This includes conclusions on the toxicity of the
substance, where appropriate, and possible establishment of an acceptable daily intake (ADI)
expressed in a numerical form with details of a dietary exposure assessment for all food categories,
including exposure of vulnerable consumer groups.
Guidance on the weight of evidence
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In the case of evaluation of food additives, the EFSA Panel on Food Additives and Nutrient Sources
added to Food (ANS Panel) has developed speciﬁc guidance describing the scientiﬁc data required for
the evaluation of a substance proposed for use as a new food additive, as well as the risk assessment
paradigm used by the Panel in drawing its conclusions (EFSA ANS Panel, 2012).
The concept developed by the ANS Panel, and described in its 2012 guidance document, is a tiered
approach which balances data requirements against other considerations such as use and animal
welfare.
Using this tiered approach, a minimal data set applicable to all compounds has been developed
under Tier 1. Compounds which are systemically absorbed or for which toxic or genotoxic effects are
found in Tier 1 will require Tier 2 testing to generate more extensive data. Tier 3 deﬁnes detailed
testing for speciﬁc a case-by-case basis. A diagram of the tiered approach is given in Figure C.1.
In 2016, the ANS Panel adopted a scientiﬁc opinion on the evaluation of the safety of the new food
additive potassium polyaspartate (A-5D K/SD) proposed for use as a stabiliser in wine at the maximum
level of use of 300 mg/L.
The opinion was further to a request from the European Commission in accordance with Regulation
(EC) No 1331/2008 establishing a common authorisation procedure for food additives, food enzymes
and food ﬂavourings.
The main question to be answered by the ANS Panel was whether potassium polyaspartate (A-5D
K/SD) was safe at the proposed uses for the EU population.
The toxicological data submitted by the applicant complied with the requirements for Tier 1 toxicity
testing as described in the 2012 ANS Panel guidance.
Hence, the ﬁrst question to be addressed by the Panel in performing the assessment was whether,
on the basis of the data submitted, any triggers for Tier 2 toxicity testing could be identiﬁed for
potassium polyaspartate (A-5D K/SD).
Provided that the toxicological data were considered sufﬁcient, the Panel addressed the question on
the estimated exposure to potassium polyaspartate (A-5D K/SD) from the proposed use as a stabiliser
in wine at the maximum proposed level of 300 mg/L.
Only the ﬁrst question will be addressed in this case study.
Based on the toxicological data provided, in line with the requirements of Tier 1 toxicity testing, the
Panel considered that no further toxicity testing was necessary. The data submitted were deemed
sufﬁcient to demonstrate that proteolytic digestion of A-5D K/SD was minimal and that no absorption
Tier 1
• Absorption 
• Genotoxicity
• In vitro testing
• Toxicity
• Extended 90-day study
Tier 2
• ADME
• Single dose
• Genotoxicity
• In vivo testing
• Toxicity
• Chronic toxicity
• Carcinogenicity
• Reproductive and developmental toxicity
• Extended one-generation toxicity studies
• Prenatal developmental toxicity
Tier 3
• ADME
• Repeat dose, volunteer studies
• Carcinogenicity
• Mode of Action
• Reproductive and developmental toxicity
• Specialised studies
• e.g. immunotoxicity, neurotoxicity, 
endocrine activity, etc
Triggers for Tier 2: 
• Systemic availability 
• Positive in vitro 
genotoxicity
Triggers for Tier 3:
• Bioaccumulation 
• Positive in vivo 
genotoxicity 
• Chronic 
toxicity/carcinogenicity 
• Reproductive/
Figure C.1: Tiered approach to toxicity testing according to EFSA ANS Panel Guidance for submission
for food additive evaluations (EFSA ANS Panel, 2012)
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of intact A-5D K/SD was observed in vitro. Both required in vitro genotoxicity tests were negative,
whereas in the 90-day toxicity study in rats no adverse effects were noted at the highest dose tested
of 1,000 mg/kg bw per day.
At the proposed maximum level of 300 mg/L, the mean dietary exposure to potassium polyaspartate
(A-5D K/SD) ranged from 0.02 to 0.4 mg/kg bw per day in adults up to 0.05 to 0.6 mg/kg bw per day in
the elderly. The high-level intake ranged from 0 to 1.4 in adults and from 0.4 to 1.8 mg/kg bw per day in
the elderly. In consideration of the proposed use of potassium polyaspartate (A-5D K/SD) as a food
additive, limited to wine, the Panel considered it appropriate to consider dietary exposure only in adults
and in the elderly.
Based on the NOAEL of the 90-day study and these exposure estimates, the Panel considered that
there would be an adequate margin of safety from the proposed use and use levels (~ 550 for the
high-level elderly consumers at the proposed maximum level of 300 mg/L). The Panel noted that the
NOAEL of 1,000 mg/kg bw per day was the highest dose tested and that the exposure used for this
comparison is a conservative estimate because the applicant indicated that, for most wines, typical use
levels of 100–200 mg/L of potassium polyaspartate would be sufﬁcient to achieve the technological
need. The Panel considers that, because of the possible uncertainties, the margin of safety estimated
above is likely to be lower than the actual margin of safety.
The Panel concluded that there was no safety concern from the proposed use and use levels of
potassium polyaspartate (A-5D K/SD) as a stabiliser in wine.
Question
On the basis of the toxicological data submitted by the
applicant as part of the dossier, are there any triggers for Tier
2 toxicity testing?
Assemble the
evidence
Select evidence The evidence was selected among the data contained in a dossier
provided in support of an application for authorisation of a new food
additive. The dossier was prepared in accordance with the data
requirements of Tier 1 toxicity testing, described in the 2012 ANS
Panel ‘Guidance for submission for food additive evaluations’
Lines of evidence No 1: Systemic availability of the proposed new food additive
potassium polyaspartate
• Sequential proteolytic attack with pepsin (porcine) and
pancreatin (porcine)
• Caco-2 cell absorption model at concentrations of 1 mg/
mL in vitro
No 2: In vitro genotoxicity of the proposed new food additive
potassium polyaspartate
• Bacterial reverse mutation assay performed in accordance
with OECD TG 471
• In vitro mammalian cell micronucleus assay performed in
accordance with OECD TG 487
No 3: Subchronic oral toxicity of the proposed new food
additive potassium polyaspartate
• A 14-day range-ﬁnding study performed to collect
information of target organs and to select appropriate
doses for a 90-day study.
• A 90-day subchronic toxicity study (OECD TG 408),
modiﬁed to include assessment of additional parameters
described in the more recent guideline on repeated-dose
28-day oral toxicity study in rodents (OECD TG 407) to
allow for the identiﬁcation of chemicals with the potential
to cause neurotoxic, immunological or reproductive organ
effects or endocrine-mediated effects
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Question
On the basis of the toxicological data submitted by the
applicant as part of the dossier, are there any triggers for Tier
2 toxicity testing?
Weigh the
evidence
Methods The data were considered to fulﬁl the requirements of Tier 1 toxicity
testing, described in the 2012 ANS Panel ‘Guidance for submission for
food additive evaluations’
The genotoxicity and subchronic toxicity studies were standard
regulatory studies carried out in recognised testing facilities according
to the relevant guideline and GLP compliance and were reported in
accordance with the relevant guideline (Best professional judgement)
Results No 1: Systemic availability of the proposed new food additive
potassium polyaspartate
• Proteolytic digestion of A-5D K/SD was minimal
• No absorption of intact A-5D K/SD was observed in vitro
No 2: In vitro genotoxicity of the proposed new food
additive potassium polyaspartate
• Both required in vitro genotoxicity tests were negative
No 3: Subchronic oral toxicity of the proposed new food
additive potassium polyaspartate
• The NOAEL in the 90-day toxicity study was 1,000 mg/kg
bw per day, the highest dose tested, and there were no
triggers for additional toxicological testing
Integrate the
evidence
Methods Data integrated according to the Tiered approach described in the 2012
ANS Panel ‘Guidance for submission for food additive evaluations’ (see
Figure C.1) (Best professional judgement)
Results In view of the Tier 1 results, the Panel considered that no Tier 2 or Tier
3 testing was necessary
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